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Abstract
Amino-terminal acetylation is a co-translational process that occurs on a majority of all eukaryotic
proteins. This modification mediates a wide range of biological processes including but not limited to
cellular apoptosis, enzyme regulation, protein localization and the N-end rule for protein degradation. The
amino-terminal acetyltransferase (NAT) enzymes that catalyze this reaction are distinguished from one
another on the basis of substrate specificity, which is dictated by the identity of the amino-terminal
sequence of the substrate protein. The NatA complex harbors the greatest diversity for substrate
selection and is responsible for acetylating a majority of all proteins that undergo this modification in
vivo. Interestingly, the major NATs exist as obligate heterodimers with one unique catalytic subunit and an
additional unique auxiliary subunit that both activates the catalytic component and anchors the complex
to the ribosome. Aberrant expression of the NatA catalytic subunit, Naa10p, as well as the auxiliary
subunit, Naa15p, has been found in numerous cancer cell tissues; consequently, NatA is an emerging
target for chemotherapeutic development.
Despite the ubiquitous nature of this modification as well as its role in oncogenesis, there is no structural
data available for any eukaryotic NAT protein. Inspired by this, we determined the x-ray crystal structures
of a series of NAT enzymes, highlighted by the structure of the 100 kDa NatA complex in the absence and
presence of a bisubstrate peptide-CoA conjugate inhibitor as well as the structure of the uncomplexed
Naa10p catalytic subunit. Additionally, we determined the structure of the independently active NatE
bound to CoA and a substrate peptide fragment and the structure of an archaeal NAT enzyme that
acetylates NatA and NatE substrates. These structures and accompanying biochemical assays are used
to delineate mechanisms of substrate binding specificity and catalysis employed by this family of
enzymes. This work provides the first scaffold for the design of NAT-specific inhibitors and lays a
foundation for understanding NAT activity at the molecular level. Furthermore, this study could have
implications for mechanisms by which regulatory subunits modulate the activity of the broader family of
protein acetyltransferases.
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ABSTRACT

THE MOLECULAR BASIS FOR AMINO-TERMINAL ACETYLATION BY NAT
PROTEINS

Glen Liszczak
Ronen Marmorstein

Amino-terminal acetylation is a co-translational process that occurs on a majority
of all eukaryotic proteins.

This modification mediates a wide range of biological

processes including but not limited to cellular apoptosis, enzyme regulation, protein
localization and the N-end rule for protein degradation.

The amino-terminal

acetyltransferase (NAT) enzymes that catalyze this reaction are distinguished from one
another on the basis of substrate specificity, which is dictated by the identity of the
amino-terminal sequence of the substrate protein.

The NatA complex harbors the

greatest diversity for substrate selection and is responsible for acetylating a majority of
all proteins that undergo this modification in vivo. Interestingly, the major NATs exist as
obligate heterodimers with one unique catalytic subunit and an additional unique
auxiliary subunit that both activates the catalytic component and anchors the complex to
the ribosome. Aberrant expression of the NatA catalytic subunit, Naa10p, as well as the
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auxiliary subunit, Naa15p, has been found in numerous cancer cell tissues; consequently,
NatA is an emerging target for chemotherapeutic development.
Despite the ubiquitous nature of this modification as well as its role in
oncogenesis, there is no structural data available for any eukaryotic NAT protein.
Inspired by this, we determined the x-ray crystal structures of a series of NAT enzymes,
highlighted by the structure of the 100 kDa NatA complex in the absence and presence of
a bisubstrate peptide-CoA conjugate inhibitor as well as the structure of the uncomplexed
Naa10p catalytic subunit. Additionally, we determined the structure of the independently
active NatE bound to CoA and a substrate peptide fragment and the structure of an
archaeal NAT enzyme that acetylates NatA and NatE substrates. These structures and
accompanying biochemical assays are used to delineate mechanisms of substrate binding
specificity and catalysis employed by this family of enzymes.

This work provides the

first scaffold for the design of NAT-specific inhibitors and lays a foundation for
understanding NAT activity at the molecular level. Furthermore, this study could have
implications for mechanisms by which regulatory subunits modulate the activity of the
broader family of protein acetyltransferases.
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CHAPTER 1

Amino-terminal acetylation: It’s not your average birthmark

1

1.1 Protein acetylation
Currently, there are thought to be 20,000-25,000 protein-coding genes in the
human genome (Clamp et al., 2007). Roughly 5% of these genes are dedicated to
enzymes that catalyze a variety of covalent protein modifications, which are able to
greatly diversify the proteome by altering the function and dynamics of expressed
proteins (Walsh et al., 2005). One of the most abundant covalent protein modifications is
acetylation, which occurs predominantly at the ε-amino group of side chain lysines and
the α-amino group at the amino-terminus of a protein (Arnesen et al., 2009; Choudhary et
al., 2009). Protein acetylation is catalyzed by bisubstrate acetyltransferase enzymes,
which facilitate the transfer of the acetyl group from the cofactor acetyl coenzyme A
(AcCoA) to a substrate protein (Figure 1.1) (Hodawadekar and Marmorstein, 2007;
Soppa, 2010). The acetylation modification neutralizes the positively charged amino
group and can effect protein-protein complex formation, protein folding, protein
degradation, and enzymatic activity, among many other processes (Kouzarides, 2000;
Starheim et al., 2012; Yuan and Marmorstein, 2013).
Histone side chain lysine acetylation is the most well characterized form of
protein acetylation (Grunstein, 1997; Sterner and Berger, 2000). Acetylation of histones
was discovered in 1964 and the connection between histone acetylation status and
transcription was immediately established (Allfrey et al., 1964). Since then, a number of
histone acetyltransferases have been biochemically and structurally characterized, and in
vivo studies have explored the role of histone acetylation in transcriptional activation and
repression through regulation of DNA-histone interactions as well as in recruitment
bromodomain-containing transcription-associated proteins (Carrozza et al., 2003; Kuo
2

and Allis, 1998; Marmorstein, 2004; Wang et al., 2008; Yun et al., 2011). Recently, the
significance and extensiveness of non-histone lysine side chain acetylation was explored
in a mass spectrometry analysis of the proteome in which a great number of acetylation
sites were identified on ~1750 non-histone proteins (Choudhary et al., 2009).
Comparatively speaking, despite the fact that amino-terminal acetylation was discovered
in 1958 and shown to occur on ~80% of all proteins by 1976, it is not well characterized
(Brown and Roberts, 1976; Narita, 1958). However, in the past decade there have been a
number of studies implicating the overexpression of amino-terminal acetyltransferases
(NATs) in oncogenesis, and as a result there has been an explosion of research activity in
the field of amino-terminal acetylation (Arnesen, 2011; Kalvik and Arnesen, 2013;
Starheim et al., 2012).
During translation, the nascent peptide chain can undergo a variety of
modifications as it emerges from the ribosome, with the two most common being
methionine excision and amino-terminal acetylation (Bradshaw et al., 1998; Kramer et
al., 2009). In eukaryotes, the co-translational process of N-terminal methionine excision
occurs on ~70% of all proteins when ~15 residues of the growing peptide are protruding
from the ribosome (Giglione et al., 2004). This process is catalyzed by the methionine
aminopeptidases (MAPs) when the second residue of the substrate protein contains a
nonbulky side chain resulting in an amino-terminal Ala-, Cys-, Gly-, Pro-, Ser-, Thr-, or
Val-. Amino-terminal acetylation occurs when there are between 25 and 50 residues
extruding from the ribosome, and is catalyzed by NAT enzymes in a sequence-specific
manner (Driessen et al., 1985; Gautschi et al., 2003; Polevoda and Sherman, 2003b).
Numerous studies have shown that amino-terminal acetylation is a very ubiquitous
3

modification, occurring on ~80% of all human proteins, ~50% of all yeast proteins and
~20% of archaeal proteins (Aivaliotis et al., 2007; Arnesen et al., 2009; Helbig et al.,
2010; Kirkland et al., 2008). In bacteria, there are only a handful of proteins that undergo
this modification (Waller, 1963). Presently, amino-terminal acetylation is believed to be
an irreversible process and that only occurs post-translationally in a select few cases (Van
Damme et al., 2011a). There are several labs that are actively trying to identify aminoterminal deacetylases as well as expand the post-translational amino-terminal acetylation
profile.
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Figure 1.1

Protein acetylation by acetyltransferase enzymes.

Histone

acetyltransferases (HATs) and other internal lysine acetyltransferases (KATs) use
AcCoA to catalyze the acetylation of ε-amino groups on internal lysine side chains.
Amino-terminal acetyltransferases use AcCoA to catalyze the acetylation of α-amino
groups on amino terminal residues. The products generated from the acetylation reaction
are acetylated peptide and CoA.

5

1.2 Biological significance of amino-terminal acetylation
Inspired by the link of aberrant expression of NATs to carcinogenesis, the
functional consequences of amino-terminal acetylation are beginning to be explored in
greater detail. While the reason that a majority of proteins undergo this modification is
still not fully understood, several key findings published recently unveil molecular
mechanisms by which amino-terminal acetylation is able to regulate a variety of
biological processes.
The N-end rule for protein degradation was discovered in 1986 and relates the in
vivo half-life a protein to the identity of its N-terminal residue (Bachmair et al., 1986).
Briefly, there exist E3 ubiquitin ligases that are able to recognize certain ‘destabilizing
residues’ at the amino terminus of a protein, which leads to ubiquitination and eventually
degradation (Figure 1.2A) (Varshavsky, 2011). Several of the residues that are not
directly recognized by these E3 ligases can be modified in a one or two step process that
eventually results in an amino-terminal arginine, which is a destabilizing residue.
Interestingly, no residue that can undergo amino-terminal acetylation can be marked for
degradation by the mechanisms described in the traditional N-end rue pathway. The Nend rule underwent a significant expansion in 2010 when Varshavsky and colleagues
reported that an amino-terminal acetyl mark could be recognized by the ubiquitin ligase
Doa10 which would subsequently lead to degradation (Figure 1.2B) (Hwang et al., 2010).
This study showed that proteins could not be degraded via this pathway in the absence of
the Doa10 E3 ligase or the NAT enzymes that catalyze acetylation of the target proteins.
This augmentation of the N-end rule is conserved from yeast to humans and is the first

6

universally applicable functional consequence of amino-terminal acetylation to be
described.
Bromodomains are protein motifs that recognize acetylated lysine residues and
mediate protein-protein interactions (Filippakopoulos et al., 2012; Mujtaba et al., 2007).
It has long been thought that a bromodomain-like motif exists for recognition of aminoterminal acetylation. In 2011, a domain within the E3 ligase Dcn1 that specifically
recognizes an amino-terminal acetyl group to facilitate protein complex formation was
reported (Scott et al., 2011). The x-ray crystal structure of this protein in complex with
an amino-terminal peptide fragment corresponding to its E2 ligase binding partner
(Ubc12) highlights a hydrophobic pocket capable of distinguishing between an aminoterminal acetyl group and other similar marks such as an amino-terminal formyl group or
an internal lysine acetyl group (Figure 1.3A). Furthermore, substrate neddylation by
Dcn1 is dependent upon amino-terminal acetylation of the Ubc12 protein. This study is
the first to present a cellular process that is regulated by amino-terminal acetylation
through control of protein-protein interactions, and it is tempting to speculate that there
exist many other proteins with a similar recognition motif that have not yet been
characterized.
The amino terminus of a protein frequently contains a signal sequence that allows
it to be targeted to the endoplasmic reticulum (ER) for post-translational processing and
secretion (Rapoport, 1992). In a study of the effect of amino-terminal acetylation on
signal sequences, it was found that cytosolic proteins were heavily biased in favor of
amino-terminal acetylation while an equal and opposite bias was observed for secretory
proteins, which must undergo ER translocation (Forte et al., 2011). This study also
7

shows that when an acetyl group is introduced to a protein that commonly undergoes
translocation, that protein is retained in the cytosol, suggesting this modification plays a
significant role in controlling protein localization (Figure 1.3B). The authors propose
that the signal recognition particle, which recognizes and targets specific proteins to the
translocon, is able to protect acetylatable amino-termini during translation to ensure
proper protein trafficking.
Metabolic regulation of NAT activity has also been observed in a study that links
amino-terminal acetylation to apoptosis (Yi et al., 2011). Overexpression of the antiapoptotic factor Bcl-xL has been shown to lower AcCoA levels by blocking secretion of
critical AcCoA precursors from the mitochondria. As a result of this decreased AcCoA
level in the cell, there is a population of proteins that do not undergo amino-terminal
acetylation. This study focuses on the effect that Bcl-xL overexpression has on a group
of caspases that must be amino-terminally acetylated to induce apoptosis (Figure 1.3C).
The experimental results from this paper suggest that when Bcl-xL is upregulated in cells,
these caspases are not amino-terminally acetylated in cells and apoptosis cannot be
carried out through this pathway.
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Figure 1.2 The N-end rule for protein degradation.

(A) The arginine pathway

includes primary destabilizing residues (black single letter amino acid representation) that
are directly recognized by E3 ligases, ubiquitinated and subsequently degraded by the
proteasome. Secondary residues (blue amino acid letters) are not directly recognized by
any E3 ligases but can be amino-terminally arginylated (green lettering) by arginine
transferases (Ate1) to inherit a primary destabilizing amino-terminal residue. Tertiary
residues (green amino acid letters) must be deamidated by Nta1 to become secondary
residues, which again are arginylated to become primary residues. (B) In the aminoterminal acetylation pathway, all residues are initially secondary destabilizing residues,
which are converted to primary residues via NAT proteins. E3 ligases can recognize the
amino-terminal acetylation mark (green lettering) and ubiquitinate the protein, marking it
for degradation by the proteasome. This figure has been adapted from Varshavsky, 2011.
9

Figure 1.3 Amino-terminal acetylation can mediate protein-protein interactions,
protein localization and apoptosis. (caption on following page)
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Figure 1.3 (continued) (A) Amino-terminal acetylation facilitates the interaction
between the E3 ligase Ubc12 (teal) and the E2 ligase Dcn1 (shown with conservation
surface). This amino-terminal acetylation-recognition pocket is conserved from yeast to
humans. (B) Amino-terminal acetylation of an endoplasmic ER signaling sequence has
been shown to inhibit protein translocation into the ER. (C) Bcl-xL (orange) blocks
secretion of citrate from the mitochondria, which reduces overall AcCoA production by
the cell. As a result, certain apoptotic effectors can no longer undergo amino-terminal
acetylation and defects in apoptosis are observed. This figure has been adapted from
Scott et al., 2011 and Starheim et al., 2012.
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1.3 Amino-terminal acetyltransferases in cancer
As evidenced by the role of amino-terminal acetylation in a wide variety of
cellular pathways, particularly apoptosis and protein degradation, it would seem that a
delicate balance of amino terminal acetylation is required for proper cellular function.
Indeed, aberrant expression of NAT enzymes has been observed in numerous cancer cell
tissues.

Interestingly, NATH (Naa15p), a component of the NatA complex, was

originally identified as an overexpressed gene in thyroid carcinoma tissues relative to
non-cancerous thyroid tissue (Fluge et al., 2002). This gene was soon found to also be
overexpressed in gastric cancer as well while its binding partner hARD1 (Naa10p) was
found to be significantly overexpressed in hepatocellular carcinomas as well as colorectal
cancer tissue, breast cancer tissue and lung cancer tissue (Kalvik and Arnesen, 2013; Lim
et al., 2006; Line et al., 2002; Midorikawa et al., 2002; Ren et al., 2008; Yu et al., 2009a;
Yu et al., 2009b).
The mechanisms by which overexpression of NAT proteins stimulate cellular
proliferation and assist in evasion of apoptosis are still being worked out, but several
studies have implicated NATs in cell cycle progression and the DNA damage response
(Arnesen et al., 2006b; Gromyko et al., 2010; Lim et al., 2006). In breast cancer, Naa10p
was found to promote passage of the G1/S and G2/M checkpoints in the cell cycle,
resulting in hyperproliferation of the MCF-7 breast cancer cell line under investigation
(Yu et al., 2009b). In a separate study, depletion of Naa10p was correlated with the
activation and stabilization of the p53 tumor suppressor protein (Gromyko et al., 2010).
As a result of Naa10p knockdown, an increase in transcription of pro-apoptotic p53dependent genes is observed in response to DNA damage and normal apoptotic pathways
12

can be carried out. Additional studies are required to analyze whether the half-life of p53
is increased as a result of decreased NAT activity or if the stabilization is through an
alternate mechanism.
As a consequence of the observations described above, NAT enzymes are
emerging targets for chemotherapeutic development (Arnesen et al., 2008). One study
used siRNA to knock down Naa10p expression in thyroid cancers with misregulation of
p53 and observed an increase in apoptotic cells (Gromyko et al., 2010). Another study
used siRNA to analyze the effect of Naa10p and Naa15p knockdown in HeLa cells and
observed a significant increase in the percent of apoptotic cells when NAT activity is
decreased (Figure 1.4A) (Arnesen et al., 2006b).

Furthermore, the activity of the

apoptosis-inducing drug daunorubicin was increased ~5-fold in the presence of siRNA
targeting the Naa10p NAT (Figure 1.4B) (Gromyko et al., 2010). These results are able
to show that inhibiting NAT activity can induce apoptosis in a variety of cancer cell
tissues and that the development of potent and selective cell-permeable inhibitors is a
worthwhile endeavor. A lack of biochemical and structural characterization of these
enzymes has left mechanisms of substrate binding and catalysis nebulous and as a result,
inhibitor development will be very challenging. Moreover, NATs are likely to share a
high degree of structural homology with HATs, which are another popular drug target.
Structural characterization of NAT enzymes will allow help to elucidate key differences
between these two families of enzymes and aid in the development of inhibitors that
specifically target NATs over HATs and vice versa (Arnesen et al., 2005).

13

Figure 1.4 Knockdown of the NatA complex can induce cell death in multiple
cancer cell lines. (A) HeLa cells (cervical cancer cell line) were transfected with 100 nM
hARD1 siRNA (siA1-2), NATH siRNA (siN-1), combination of NATH and hARD1
siRNAs (100 nM each), control siRNA (siL-100 and siL-200) or transfected with
Oligofectamine only (siRNA-). The percent of apoptotic cells resulting from each siRNA
transfection is shown. (B) Depletion of NatA sensitized CAL-62 cells (thyroid cancer cell
line) to treatment with the Daunorubicin, a DNA intercalating drug that is FDA approved
for the treatment of certain cancers. Reductions in cellular proliferation are shown. This
figure has been adapted from Arnesen et al., 2006b and Gromyko et al., 2010.
14

1.4 Amino-terminal acetyltransferase enzymes
There are three major NAT complexes that are responsible for modifying ~85%
of all proteins that undergo amino-terminal acetylation in vivo (Arnesen et al., 2009;
Starheim et al., 2009b).

These complexes, called NatA, NatB and NatC, are well

conserved from yeast to humans, exist as obligate heterodimers, and are differentiated
from one another on the basis of substrate specificity (Figure 1.5A) (Polevoda et al.,
1999; Polevoda and Sherman, 2003a). Each complex consists of one unique catalytic
subunit and an additional unique auxiliary subunit that both activates the enzymatic
component and anchors the complex to the ribosome during translation (Gautschi et al.,
2003; Polevoda et al., 2008). Three additional NAT enzymes, NatD-NatF, have also
been identified but they have a limited set of biologically relevant substrates, appear to be
independently active, and are not well characterized across eukaryotes (Evjenth et al.,
2009; Gautschi et al., 2003; Hole et al., 2011; Polevoda et al., 2009; Song et al., 2003;
Van Damme et al., 2011b).
The NatA complex harbors the most diversity for substrate selection and is
responsible for modifying the majority of all amino-terminally acetylated proteins in vivo
(Arnesen et al., 2009; Polevoda et al., 1999). NatA is the only NAT complex with the
ability to acetylate the α-amino group of non-methionine amino-terminal residues; it will
acetylate an α-amino group of an amino-terminal Ala-, Cys-, Gly-, Ser-, Thr-, or Val- on
a nascent peptide chain (Polevoda and Sherman, 2003b). Interestingly, the only NAT
proteins that have been found to be upregulated in cancer are components of the NatA
complex, making this NAT the most clinically relevant of all the NAT enzymes (Kalvik
and Arnesen, 2013).
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The heterodimeric NatA complex contains the Naa10p catalytic subunit (MW~20
kDa) and the Naa15p auxiliary subunit (MW~80 kDa) (Arnesen et al., 2005; Mullen et
al., 1989; Park and Szostak, 1992). Naa10p is believed to be a member of the GNAT
family of acetyltransferases based on the similarity of its sequence to known GNAT
proteins (Vetting et al., 2005). There is comparatively far less known about the structure
and activating mechanism of Naa15p, largely owing to the fact that there are no proteins
with appreciable sequence similarity that have been structurally characterized. Protein
domain identification servers have been used to analyze the sequence of Naa15p and
predict that it contains a coiled coil region and at least 4 tetratricopeptide (TPR) motifs
(Arnesen et al., 2005; Blatch and Lassle, 1999). Notably, biochemical characterization of
NatA has been hampered by the fact that there is currently no protocol available for
recombinant expression of the complex.
The NatB and NatC complexes are also obligate heterodimers that can physically
associate with the ribosome (Polevoda et al., 2003; Rigaut et al., 1999; Starheim et al.,
2008; Starheim et al., 2009a; Tercero and Wickner, 1992; Van Damme et al., 2012). A
third subunit of the NatC complex has been identified that may enhance activity of the
dimer, but is not required for activity (Polevoda and Sherman, 2001). Both of these
complexes acetylate the α-amino group of substrate peptides with an amino-terminal
methionine residue, with further specificity dependent up the identity of the second
residue; NatB is active towards peptides with a hydrophilic second residue while NatC is
active towards peptides with a hydrophobic second residue (Polevoda et al., 1999;
Polevoda and Sherman, 2003b; Tercero et al., 1993). Like NatA, there is no structural
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data available for any component of either of these complexes and recombinant
expression of the complexes has not yet been worked out.
Of the three NATs that show activity in the absence of a regulatory protein
subunit (NatD-NatF), NatE (Naa50p) is the only one that has been recombinantly
expressed (Evjenth et al., 2009).

In a recent study focused on the biochemical

characterization of Naa50p, the recombinant protein was able to acetylate the α-amino
group of a peptide with an amino-terminal Met-Leu-Gly-Pro- sequence, which
corresponds to the protein hnRNP F, the only Naa50p substrate identified in vivo
(Arnesen et al., 2009). Additional kinetic analysis revealed that while the amino-terminal
methionine is required for activity, the identity of downstream residues is less crucial
(Figure 1.5B) (Evjenth et al., 2009). Despite the fact that only one biologically relevant
substrate is known, the Naa50p enzyme was shown to be required for proper sister
chromatid cohesion in humans and fruit flies, a process that does not involve the hnRNP
F protein (Hou et al., 2007; Pimenta-Marques et al., 2008; Williams et al., 2003). It is
therefore likely that this enzyme has other biologically relevant substrates that have not
yet been identified. The enzyme was also screened against many proteins known to
contain acetylation-susceptible internal lysines and no significant acetylation could be
detected (Evjenth et al., 2009). Interestingly, this protein has been found to physically
associate with the NatA complex (Arnesen et al., 2006a; Gautschi et al., 2003).
Preliminary experiments show that Naa50p is not catalytically stimulated by this
interaction, suggesting that recruitment to the ribosome is likely to be the sole purpose for
this interaction (data not shown).
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Figure 1.5

NAT substrate specificities.

(A) The three known eukaryotic NAT

complexes are shown bound to a translating ribosome. The substrate specificities for
each NAT are listed below the complex corresponding complex. (B) Biochemical
characterization of NatE with a variety of substrate peptides. The ‘RRR24’ portion of the
peptide represents a 20-amino acid basic tag that was used to isolate the peptide after the
acetylation reaction. This figure has been adapted from Starheim et al., 2012 and Evjenth
et al., 2009.
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1.5 Dissertation objectives
There is a substantial lack of biochemical and structural data available for
enzymes that facilitate the very ubiquitous modification of amino-terminal acetylation.
Currently, the bacterial RimI enzyme is the only NAT structure available and
mechanisms of substrate binding and catalysis employed by NAT enzymes remain
mostly unexplored (Vetting et al., 2008). Structural and biochemical characterization of
NATs, particularly the NatA complex, would uncover unique features that could be
exploited for the development of potent and specific inhibitors with chemotherapeutic
application (Arnesen et al., 2008).

Furthermore, in the broader family of

acetyltransferases, there are several enzymes that require binding partners for catalytic
activity such as HAT1, Sas2 and HBO1 (Iizuka and Stillman, 1999; Parthun et al., 1996;
Sutton et al., 2003).

Despite the observation that many acetyltransferases require

regulatory subunits for optimal activity, no acetyltransferase has been characterized in the
presence of its activating partner.
The focus of my dissertation is on determining the molecular basis for substrate
binding, acetylation specificity, and catalysis exhibited by the NatA complex, and to
determine the role of the auxiliary subunit in these activities. I also set out to structurally
and biochemically characterize the Naa50p enzyme, which independently acetylates
substrates with a Met- amino-terminal residue. To this end I solved the structure of
Naa50p bound to a substrate peptide as well as the structure of Naa10p in the absence and
presence of the Naa15p regulatory subunit and a bisubstrate inhibitor. Additionally, I
characterized an archaeal NAT that is able to acetylate NatA and Naa50p substrates.
This study was able to validate the mechanisms I proposed for acetylation by NatA and
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Naa50p and also has implications for the evolution of substrate-specific acetylation by
eukaryotic NAT enzymes. Through the use of x-ray crystallography and structure-based
biochemical assays I was able to:
(1) Identify mechanisms by which these enzymes are able to preferentially acetylate
α-amino groups over ε-amino groups.
(2) Show a conserved NAT tertiary structure that appears to be required for catalytic
activity.
(3) Uncover the mechanisms that these enzymes use to acetylate substrates in a
sequence-specific manner.
(4) Characterize the first mechanism of acetyltransferase activation by an obligate
binding partner.
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CHAPTER 2

Structure of the ternary Naa50p amino-terminal acetyltransferase complex reveals
the molecular basis for substrate-specific acetylation

"This research was originally published in the Journal of Biological Chemistry (Liszczak
et al., 2011) © the American Society for Biochemistry and Molecular Biology."
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2.1 Introduction and summary of conclusions
To understand the molecular basis for how NAT proteins such as Naa50p mediate
catalysis and selectively target the α-amino group of amino-terminal residues over the εamino group of side-chain lysine residues, we determined the x-ray crystal structure of a
ternary Naa50p complex with coenzyme A and a cognate amino-terminal substrate
peptide, and carried out structure based mutagenesis as well as accompanying
biochemical and enzymatic characterization. We find that the peptide backbone of the
substrate is anchored to the protein through a series of backbone hydrogen bonds with the
first methionine residue specified through multiple van der Waals contacts, together
creating an α-amino methionine-specific pocket.

We also employ structure-based

mutagenesis that supports the importance of the α-amino methionine-specific pocket of
Naa50p and is consistent with the proposal that conserved histidine and tyrosine residues
play important catalytic roles. Superposition of the ternary Naa50p complex with the
peptide-bound Gcn5 histone acetyltransferase (HAT) reveals that the two enzymes share
a GNAT (Gcn5-related N-acetyltransferase) fold, but differ in their respective substrate
binding grooves such that Naa50p can accommodate only an α-amino substrate and not a
side-chain lysine substrate that is acetylated by lysine acetyltransferase (KAT) enzymes
such as Gcn5 (Poux et al., 2002; Rojas et al., 1999). The structure of the ternary Naa50p
complex also provides the first molecular scaffold for the design of NAT specific small
molecule inhibitors with possible therapeutic applications.

2.2 Results
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2.2.1 Naa50p shows a GNAT fold with a more constricted protein substrate-binding site
Crystals of the Naa50p•CoA•substrate peptide ternary complex formed in the
space group P21 with three molecules in the asymmetric unit and diffracted to a 2.75Å
resolution limit. The structure was refined to an Rfree/Rwork of 19.0/25.4% with good
stereochemistry and 96.9% of the residues in the favored region of the Ramachandran
plot (Table 2.1). The structure reveals a mixed α/β-fold with a conserved AcCoA binding
core region composed of one α-helix (α3) and three β-strands (β2- β4) as seen in Figure
2.1A.

This motif is characteristic of the GCN5-related histone N-acetyltransferases

(GNATs) and allows us to confidently place Naa50p into this family of enzymes
(Neuwald and Landsman, 1997). Indeed, Naa50p superimposes well with the HAT
domain of Gcn5 with an RMS deviation of Cα atoms of 4.1 Å (Figure 2.1B). In addition
to a high degree of superposition within the core domain, the entire β-sheet that cuts
through the center of the structure (β1-β5 and β7) and the α1-turn-α2 that flanks one side
of the protein substrate-binding site superimpose well (Figure 2.1B).

The greatest

regions of divergence between the two proteins map to C-terminal segments of the two
proteins that flank the opposing side of the respective protein substrate-binding site,
which maps to an unconserved region in the GNAT superfamily of proteins (Neuwald
and Landsman, 1997; Trievel et al., 1999). In the case of Gcn5, this region forms a loophelix-loop-strand motif that facilitates the formation of a relatively wide protein substrate
binding site, while in the case of Naa50p, this regions forms a β-hairpin (β6-loop-β7)
containing a relatively long 14-residue loop that blocks off part of the protein substrate
binding site that is otherwise accessible in Gcn5 (Figure 2.1B and 2.2A).
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In addition to well ordered electron density for the entire CoA molecule, we
observed strong electron density in the Fo-Fc map corresponding to the first 4 residues of
the 10-residue peptide that was used for the crystal structure (Figure 2.1A and 2.2B).
Following refinement, side chain density was visible for the first two residues of the
peptide while backbone density could be traced to the fourth residue (Figure 2.1A). This
correlates with the contacts formed between the peptide and the enzyme in the crystal
structure (Figure 2.2B and 2.2C). Hydrogen bonding can be observed throughout the
backbone for the first two residues and the Met1 and Leu2 side chains both sit in
hydrophobic pockets that appear to be tailored for these residues (Figure 2.2B and 2.2C).
There are no substantial interactions beyond the leucine backbone carbonyl group seen in
the structure. The overall thermal B-factor of the peptide is 73.9 Å2, which is high in
relation to the overall thermal B-factor of the protein (55 Å2). This discrepancy can be
accounted for by the skewed nature of the B-factors of the individual residues of the
peptide. The Met1 has a B-factor of 62 Å2 and this value increases for each residue of the
peptide that extends out of the binding pocket, with the Pro4 B-factor reaching 93 Å2. For
comparison, the atoms of CoA have an average B-factor of 50 Å2. Superposition of the
ternary complex with the Naa50p•AcCoA binary complex (PDB code: 2OB0) shows no
significant structural rearrangement upon substrate peptide binding (Figure 2.3), further
revealing that Naa50p does not undergo significant structural change upon protein
substrate binding.
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Table 2.1 Data collection and refinement statistics for the Naa50p•CoA•peptide
complex.

Values in parentheses are for the highest resolution
shell. Rfree was calculated using 10% of the
reflection data chosen randomly and omitted at the
start of refinement.
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Figure 2.1 Overall structure of the ternary Naa50p•CoA•peptide complex. (caption
on following page)
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Figure 2.1 (continued) (A) Structure of the ternary complex showing Naa50p in teal
cartoon, Coenzyme A in magenta stick with C, N and S atoms in CPK coloring and
substrate peptide in yellow stick with C, N and S atoms in CPK coloring. Substrate
peptide electron density obtained from a composite omit map (blue) is shown contoured
to 1.5σ. (B) Superposition of the Naa50p ternary complex with the ternary Gcn5 HAT.
The Gcn5 enzyme and accompanying substrate peptide (orange) are shown in cartoon
format. The substrate peptides for each enzyme are shown as thicker cartoons for clarity.
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Figure 2.2 Naa50p interaction with the substrate peptide. (caption on following
page)
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Figure 2.2 (continued) (A) Surface of Naa50p highlighting the peptide substrate binding
site with the peptide shown in stick representation with the same color-coding as in
Figure 1.1A. (B) A ChemDraw representation summarizing all the interactions between
Naa50p and peptide. Hydrogen bonding interactions are denoted with dotted lines and
van der Waals interactions are depicted with archs. (C) A stereo diagram of Naa50p
interactions with substrate peptide. Protein residues that make peptide interactions are
highlighted. The His112 side chain has been omitted for clarity. Substrate peptide
resides are labeled with yellow numbers corresponding to their sequential order.

(D)

Sequence alignment of Naa50p orthologues from several species. The names of the
orthologs are abbreviated as follows: Atha, Arabidopsis thaliana; Odio, Oikopleura
dioica;
vinifera.

Ptri, Populus trichocarpa;

Smoe, Selaginella moellendorffii;

Vvin, Vitis

For comparison, two Naa10p orthologues are also shown. Spom, is

Schizosaccharomyces pombe. Numbering and secondary structure elements for Naa50p
are indicated above the Naa50p sequence. Residues of Naa50p that contact the peptide
backbone (+), Met1 (), Leu2 () and catalytic residues (*) are highlighted with the
indicated symbols above the Naa50p sequence.
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Figure 2.3 Naa50p•AcCoA versus Naa50p•CoA•peptide. Superposition of the ternary
Naa50pCoApeptide complex reported here (aqua) with the binary Naa50pAcCoA
complex (pink) (PDB ID: 2OB0) revealing no significant structural rearrangement upon
substrate peptide binding. The AcCoA of the binary complex has been removed for
clarity.
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2.2.2 The Naa50p protein substrate binding site is ideally suited to accommodate an amino group of an N-terminal Met- peptide
The amino-terminal peptide substrate points into the protein active site with the
backbone roughly perpendicular to the central -sheet and parallel to the pantothenate
arm of the CoA (Figure 2.1A and 2.2A). The peptide is anchored to the protein through a
series of hydrogen bonds between the side chains of Tyr31 and Tyr139 and the backbone
carbonyl atoms of Met75 and His112 (Figure 2.2C). The amino-terminal methionine
residue sits in a hydrophobic pocket composed of Phe27, Pro28 and Val29 from the 12 loop and Tyr139 and Ile142 from the 7 hairpin loop, which each make van der
Waals contacts to Met1 of the peptide. The Leu2 residue also sits in a hydrophobic pocket
formed by Tyr31, Phe35 from the 1-2 loop segment, Tyr138 from the 6-7 hairpin
loop and Tyr 73 and Met 75 from the 4 strand (Figure 2.2C). There are also hydrophilic
groups in the vicinity of Leu2 such as the hydroxyls of tyrosines 73 and 138 and the
guanidinium group of Arg62 (Figure 2.2C), which provides an explanation for the ability
of Naa50p to acetylate a substrate with a hydrophilic residue at the second position.
Consistent with the importance of the amino acid composition of the aminoterminal side chain-binding pocket, each of these residues is highly conserved within the
Naa50p orthologues from other species (Figure 2.2D). In particular, the residues that
contact the peptide backbone (Tyr31, Met75, His112 and Tyr139) and Met1 (Phe27,
Pro28, Val29, Tyr139 and Ile142) are strictly conserved and residues that contact Leu2
(Tyr31, Phe35, Tyr73, Met75 and Tyr138) are strictly or highly conserved (Figure 2.2D).
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To directly establish the functional importance of Naa50p residues that appear to
make important peptide substrate contacts in the crystal structure we targeted several of
these residues for mutagenesis followed by enzymatic characterization of the mutant
proteins. Each mutated residue was changed to alanine and the catalytic efficiency of
each mutant was determined and compared to the wild-type protein. Each mutant was
purified to homogeneity and exhibited gel filtration chromatography elution profiles
identical to that of the wild type construct. To further confirm that the mutant proteins
were folded properly they were subjected to circular dichroism experiments, each
revealing a similar spectrum to the wild-type protein (data not shown). Notably, each of
the mutant proteins showed defects in catalytic efficiency, with most of the mutant
proteins showing no detectable activity (Figure 2.4 and Table 2.2). Of the residues that
contact the peptide backbone, Tyr31, His112 and Tyr139, were mutated and each of these
mutants showed no detectable activity, arguing for the importance of these residues for
backbone interaction, although Tyr31 also participates in Leu2 peptide contact and
His112 likely participates directly in catalysis, as will be described below (Figure 2.4 and
Table 2.2). Of the residues that contact Met1 of the peptide, the Phe27 mutant showed
no detectable activity, while the Pro28 and Val29 mutants showed at least an 85%
reduction in activity. The Tyr139 mutant showed no detectable activity and Ile142
retained about 40% activity (Figure 2.4 and Table 2.2). Mutants of Leu2 peptide contact
residues Tyr31, Phe35 and Tyr73 each showed no detectable activity (Figure 2.4 and
Table 2.2).

Taken together, the structure-based mutagenesis is consistent with the

functional importance of the protein-peptide substrate interactions observed in the crystal
structure.
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Figure 2.4 Catalytic efficiency of Naa50p and mutant proteins. Four data points
were collected for each enzyme in triplicate. The straight line formed by these four data
points crosses through the origin, indicative of the fact that their slope can be used to
calculate catalytic efficiency.
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Table 2.2 Catalytic efficiency of Naa50p wild type enzyme and mutants.

*Mutants that did not yield detectable
activity at 2.0 mM substrate peptide and a
saturating amount of AcCoA are labeled
ND.
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2.2.3 Tyr73 and His112 likely play catalytic roles through an ordered water molecule
Analysis of the Naa50p active site reveals that only two residues are in position to
function in catalysis, Tyr73 and His112 (Figure 2.5A). Although the functional groups of
these residues could participate in proton extraction of the amino nitrogen substrate, the
hydroxyl of Tyr73 and the imidazole nitrogen of His112 are too far for direct proton
extraction. To potentially circumvent this issue, a well ordered water molecule, with a Bfactor of 48 Å2, is in a position to mediate proton abstraction. This molecule is held in
place via hydrogen bonds with the peptide amino-terminal α-amine group, and the
backbone carbonyl and nitrogen of Ile74 and His112, respectively (Figure 2.5A).
Supporting the role of such a water molecule, the GNAT histone acetyltransferase Gcn5
has been shown to employ a glutamate residue to mediate proton abstraction from the
substrate peptide through a well-ordered water molecule (Rojas et al., 1999). An active
site alignment of these two proteins shows that Tyr73 of Naa50p aligns very well with
the catalytic Glu122 of Gcn5 (Figure 2.5B), which supports a role of Tyr73 of Naa50p as
participating in catalysis (Tanner et al., 1999). Further supporting the catalytic roles of
Tyr73 and His112 of Naa50p is a superposition of the Naa50p active site with the active
site of the bacterial NAT protein RimI (Figure 2.5B) (Vetting et al., 2008).

This

superposition illustrates that the catalytic glutamate general base residue of RimI sits
roughly midway between Tyr73 and His112 of Naa50p and that RimI also contains a
well-ordered water molecule in a similar position to the corresponding water molecule of
Naa50p.
To directly probe the functional importance of Naa50p Tyr73 and His112, we
mutated these residues individually to both alanine and phenylalanine, purified these
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proteins to homogeneity, confirmed that these proteins were properly folded by circular
dichroism and analyzed their catalytic properties. As can be seen in Table 2.2, each of
the mutants showed background levels of catalytic activity consistent with a role for
Tyr73 and His112 in catalysis by Naa50p, although other non-catalytic effects of
mutating Tyr73 and His112 cannot be ruled out. We also carried out a pH-rate profile of
wild-type Naa50p from pH 8.0 to 6.0, the most acidic environment at which activity
could still be measured (Figure 2.5C). As can be seen in Figure 2.5C, the wild-type
enzyme shows optimal activity at above pH 7.5 and the kcat decreases about 3-fold when
the pH is decreased to 6.0. The inflection point at ~pH 7.0 could represent the pKa of the
catalytic base or that of the substrate α-amino group in the active site. While a pH of 7.0
is reasonable for the imidazole side chain, one would expect a more drastic catalytic
effect once the side chain is fully protonated if the histidine was the only residue that
participated in proton abstraction.

Taken together, this data is consistent with the

proposal that Tyr73 and His112 cooperate in functioning as general bases for catalysis
that proceeds through the ordered water molecule observed in the crystal structure.
Tyr73 and His112 do not appear to be in proper position in the current structure to act as
general acids for reprotonation of the CoA leaving group, although it is possible that one
of these residues or a different protein residue might swing into place to play this role
following the acetyl-transfer.
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Figure 2.5 The Naa50p active site. (A) Detailed view of the active site highlighting an
ordered water molecule that plays a putative catalytic role along with Tyr73 and His112
in proton extraction from the α-amino group of the peptide substrate. Hydrogen bonds are
depicted with a gray dashed line. Substrate peptide resides are labeled with yellow
numbers corresponding to their sequential order. (B) Superposition of the Naa50p active
site with the active sites of bacterial RimI and the Gcn5 HAT. RimI and Gcn5 substrates,
catalytic residues and water molecule are shown in pink and orange, respectively. (C)
pH-rate profile for wild type Naa50p. See the methods section for details.
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2.2.4 Comparison to the Gcn5 ternary complex suggests why Naa50p prefers N-amino
vs. side chain lysine substrates
While there have been several reports of NATs performing internal lysine
acetylation, it is clear that the process is very slow in relation to the observed α-amino
acetyltransferase activity (Evjenth et al., 2009; Seo et al., 2010). To better understand the
structural basis for Naa50p preference for N-terminal acetylation, we superimposed the
ternary Naa50p complex with the tGCN5•CoA•H3 peptide complex in order to identify
key differences in substrate peptide binding motifs (PDB ID: 1QSN) (Rojas et al., 1999).
As noted earlier, the two structures share a similar overall fold with the most pronounced
differences mapping to the C-terminal segment of the proteins and particularly to the β6β7 loop flanking one side of the protein peptide binding site (Figure 2.6A). As a result of
this difference, one side of the Naa50p protein substrate-binding site is constricted such
that a lysine side-chain containing peptide segment cannot sit across the substrate
binding-groove (Figure 2.6B).

Indeed, Ile142 of the β6-β7 loop makes van der Waals

interactions with Pro28 and Val29 of the α1-α2 loop across the binding groove and
Arg141 also sits across the binding groove (Figure 2.6A). Since the more constricted
Naa50p substrate-binding site cannot easily accommodate a peptide sitting across the
substrate-binding site, it must accommodate a peptide substrate that enters the active site
in a different orientation. This is consistent with the binding mode of the amino-terminal
peptide that enters the active site from the accessible end of the peptide binding groove
and at roughly a 90° angle relative to the histone H3 peptide bound to Gcn5 (Figure
2.1B). Residues that participate in constricting one end of the Naa50p binding groove,
Pro28, Val29 and Ile142, also participate in amino-terminal peptide binding (Figure
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2.2C).

The unique features that differentiate Naa50p from Gcn5 are conserved in the

RimI structure (Figure 2.6C) and we extrapolate that they are conserved throughout the
NATs to mediate amino-terminal acetylation specificity.
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Figure 2.6

Structural comparison with other acetyltransferases.

(A) Structural

alignment of Naa50p with the Gcn5 HAT. The proteins are shown in cartoon with the
peptide substrates shown in stick figure with CPK coloring. The CoA molecule from
Naa50p is also shown in stick figure. The zoom view (rotated 30° clockwise on the yaxis) shows a stereo image that includes the position of several side chains in the Naa50p
substrate binding loops. (B) Surface representation of Naa50p with a stick model of the
Gcn5 substrate peptide docked into the Naa50p peptide-binding site. (C) Structural
alignment of Naa50p with the bacterial NAT RimI. The Rim protein is shown in purple
cartoon with the associated bisubstrate inhibitor shown in purple stick figure with CPK
coloring.
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2.3 Discussion
Despite its biological importance, the process of amino-terminal protein
acetylation remains relatively poorly understood. In contrast, histone acetyltransferases
(HATs) that modify side-chain lysine residues have been extensively characterized at
both the biochemical and structural levels, and this understanding has led to the
development of HAT specific inhibitors (Bowers et al., 2010; Furdas et al., 2011; Wu et
al., 2011). The ternary structure of Naa50p bound to CoA and a peptide fragment of its
native substrate reported here now provides the first molecular insights into the
mechanism of substrate binding and possibly also catalysis used by this class of enzymes
and provides a molecular scaffold for the design of NAT specific inhibitors.
The stringent requirement of Naa50p for a substrate containing an amino-terminal
methionine is well explained by the structure and accompanying mutagenesis and
enzymology studies. The enzyme uses a hydrophobic pocket that forms van der Waals
contacts with the methionine residue, which prevents the enzyme from interacting with
all other potential amino-terminal residues. BLAST alignments reveal that these residues
are highly conserved among Naa50p homologues but not in Naa10p orthologues (Figure
2.2D). It is likely that the corresponding residues in Naa10p are optimized to be more
tolerant of amino acid variability in this position. Notably, most of the Naa50p residues
that mediate peptide backbone interactions (Tyr31, His112 and Tyr139) are conserved
with the Naa10p proteins, suggesting that the binding mode of the amino-terminal protein
segment to the Naa10p proteins might be similar to that of Naa50p. The interactions
between Naa50p and peptide residues C-terminal to Met1 are less extensive, which allows
for more flexibility in substrate residue identity at these positions (Figure 2.2C).
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Previous studies show that Naa50p activity is effected by the first four residues of the
substrate peptide sequence (Evjenth et al., 2009). Here, we have been able to provide an
explanation for the ability of the enzyme to accommodate both hydrophobic and
hydrophilic residues at the second amino acid position of the substrate. The third and
fourth substrate residues in the structure presented here are partially disordered and so it
is difficult to draw conclusions regarding their role in substrate binding from the
structure. A point mutation screen shows that conservative mutations in the third and
fourth positions are tolerated quite well, with the most detrimental mutations at these
positions exhibiting only a 5-fold reduction in Km and a modest effect on kcat (Evjenth et
al., 2009). This is in contrast to the more drastic effects on mutations of Met1 or Leu2.
The GNAT family of enzymes has been shown to employ a variety of different
chemical strategies to perform protein acetylation. For example, the Gcn5/PCAF family
of HATs uses a conserved glutamic acid residue to serve as a general base for a ternary
complex mechanism (Clements et al., 1999; Langer et al., 2001), the p300/CBP family
does not employ a dedicated general base for catalysis but likely uses a tyrosine residue
as a general acid to mediate a Theorell-Chance catalytic mechanism (Liu et al., 2008).
Interestingly, the MYST family of histone acetyltransferases use a ping-pong mechanism
in which the glutamate general base first catalyzes the acetyl-transfer to a conserved
cysteine residue and then catalyzes a second deprotonation step to facilitate transfer of
the same acetyl group to a substrate lysine residue (Holbert et al., 2007; Yan et al., 2002;
Yuan et al., 2012).

In addition, the small molecule acetyltransferase, serotonin

acetyltransferase, employs two histidine residues to act as general bases for catalysis, and
it is likely that the archaeal protein acetyltransferase (PAT) enzymes use multiple
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residues as bases in its mechanism as well (Brent et al., 2009; Hickman et al., 1999;
Scheibner et al., 2002). In light of the varied ways in which acetyltransferase enzymes
carry out chemistry, it is not surprising that Naa50p appears to use yet another chemical
strategy that likely involves histidine (His112) and tyrosine (Tyr73) general base
residues, at least one of which might function as a general acid as well (Figure 2.5A).
It is also of note that the in vitro catalytic parameters derived in this study are
inefficient relative to other acetyltransferases (which are measured on a sec-1 scale). The
slower rate observed for the recombinant Naa50p may be a consequence of the absence
of the Naa15p or Naa10p subunits, which might function to elevate the catalytic rate. It
is also possible that there exists a subset of unidentified Naa50p substrates that the
enzyme is able to acetylate with a more biologically relevant enzymatic rate.
Finally, this study represents the first description of the molecular details that
distinguish the substrate binding modes between the amino-terminal and side-chain lysine
protein acetyltransferases. There appear to be several features of the Naa50p protein
substrate binding site that center around an extended β6-β7 hairpin loop, which plays a
particularly important role in biasing the specificity of the NAT proteins for aminoterminal α-amino groups. Our results are therefore in agreement with previous studies
that have shown that Naa50p is a very inefficient lysine side-chain acetyltransferase
(Evjenth et al., 2009). We also anticipate that the ternary Naa50p scaffold provided here,
along with the distinguishing features between NATs and KATs, may lead to the
development of NAT specific inhibitors that might have therapeutic applications.
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2.4 Materials and methods
2.4.1 Naa50p expression and purification
A pETM-GST vector (G. Stier, EMBL, Germany) containing DNA encoding the
full length human Naa50p (1-169) fused to GST through a tobacco etch virus (TEV)
protease cleavable site was transformed into BL21 (DE3) cells. The transformed cells
were cultured at 37°C until the cell OD600 reached ~0.7, induced for protein expression
with 0.5mM isopropyl 1-thio-β-D-galactopyranoside and grown overnight at 18°C. Cells
were isolated by centrifugation and lysed by sonication in a lysis buffer containing 25
mM HEPES, pH 7.5, 100 mM NaCl, and 10mM 2-mercaptoethanol. The supernatant
was isolated and passed over GST-binding resin (Clonetech). Unbound proteins were
washed off the resin with lysis buffer and TEV protease was added directly to the resin
and allowed to incubate overnight at room temperature. Untagged Naa50p was washed
off the resin with lysis buffer, collected, dialyzed into a buffer containing 25 mM
HEPES, pH 7.5, 50 mM NaCl, and 10 mM 2-mercaptoethanol and bound to a 5 mL
HiTrap SP ion exchange column (GE Healthcare). The protein was eluted in the same
buffer using a salt gradient of 50-750 mM NaCl and further purified to homogeneity
using a Superdex 75 gel filtration column (GE Healthcare) in a storage buffer containing
25mM HEPES, pH 7.5, 100 mM NaCl, and 10 mM dithiothreitol.

Peak fractions

containing protein that was greater than 95% pure as judged by SDS-PAGE was
concentrated to ~ 12 mg/ml using a 10 kDa protein concentrator (Millipore) and stored at
–70°C until further use. All protein mutants were generated using the QuikChange
protocol from Stratagene (Braman et al., 1996). Protein harboring point mutations was
obtained following the expression and purification protocols described above.
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2.4.2 Crystallization and data collection
The peptides and Coenzyme A used in crystallization were purchased from
GenScript and Sigma-Aldrich, respectively. The Naa50p•CoA•peptide ternary complex
was prepared for crystallization by mixing in a 1:3:3 molar ratio, respectively. The
length of the substrate peptide was varied between 7-20 amino acids in crystallization
trials. The protein concentration used in crystallization was 12 mg/mL and the peptide
that produced the best diffracting crystals was a 10-mer with the sequence
MLGPEGGRWG. Crystals of the ternary Naa50p•CoA•peptide complex were grown by
hanging drop vapor diffusion at 20°C over 1-3 days against a reservoir solution
containing 16% PEG 8000, 20% glycerol and 40 mM potassium phosphate (monobasic),
pH 5.0.

Crystals were transferred to a harvest solution containing well solution

supplemented with 25% glycerol prior to flash freezing in liquid nitrogen. Data was
collected at Beamline X6A at the National Synchrotron Light Source (Brookhaven
National Labs) and processed using HKL2000 (Otwinowski and Minor, 1997).

2.4.3 Structure determination and refinement
The structure of the ternary Naa50p•CoA•peptide complex was determined by
molecular replacement with Phaser in the CCP4 suite of programs using the Naa50p•CoA
binary complex (PDB ID: 2PSW) as a search model (McCoy et al., 2007). Solvent
molecules and CoA were excluded from the search model. Structure refinement was
performed by initially applying 3-fold non-crystallographic symmetry (NCS) and running
Phenix.Refine with Group ADPs (atomic displacement parameters) for the initial cycles
45

(Adams et al., 2010). Subsequently, CoA and substrate peptide were built into the
resulting Fo-Fc electron density map and additional refinement was performed manually
using the molecular graphics program Coot (Emsley and Cowtan, 2004). In advanced
stages of refinement, NCS restraints were released, individual ADPs were refined and
solvent was added. The final model was checked for errors against a composite omit map
generated in CNS (Brunger et al., 1998). Refinement statistics can be found in Table 1.
The final model and structure factors were submitted to the Protein Data Bank with PDB
ID 3TFY.

2.4.4 Acetyltransferase activity assays
Naa50p acetyltransferase assays were carried out with 100 nM untagged, full
length enzyme at 37°C for 40 minutes in 100 mM Tris, pH 8.0 and 50 mM NaCl unless
stated otherwise. A saturating amount of AcCoA (300 µM) was used in all enzymatic
reactions

and

substrate

peptide

(+NH3-MLGPEGGRWGRPVGRRRRP-COO-,

GenScript) concentration was varied to determine steady state catalytic parameters. In
the assay, radiolabeled [14C] Acetyl coenzyme A (4 mCi/mmol, PerkinElmer) was mixed
with substrate peptide and allowed to incubate with enzyme in a 25 µL reaction volume.
To quench the reaction, 20 µL of the reaction mixture was added to P81 paper discs
(Whatman) and the paper discs were immediately placed into wash buffer. Washes were
then carried out three times in 10 mM HEPES, pH 7.5, with each wash lasting 5 minutes,
to remove unreacted AcCoA. The papers were then dried with acetone, added to 4mL of
scintillation fluid, and the signal was measured using a Packard Tri-Carb 1500 liquid
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scintillation analyzer. Background control reactions were performed in the absence of
enzyme. Reactions were also performed in the absence of substrate peptide to ensure that
any possible signal due to autoacetylation was negligible. Substrate peptide Km and Vmax
parameters were derived by titrating substrate peptide at 8 different concentrations
ranging from 100µM-1500 µM in the presence of 300 µM AcCoA. Complications
caused by TFA from the addition of high concentrations of substrate peptide prevented
point mutant catalytic assays from reaching a saturating amount of peptide, and so we
instead analyzed the catalytic efficiency (kcat/Km) of these mutants. By keeping the
substrate concentration far below Km, we were able to plot velocity vs. [peptide] and use
the slope of the resulting line to obtain kcat/Km values for several of these mutants based
on the equation: v=(kcat/Km) [E][S]. These results allowed us to quantitatively compare
the catalytic efficiencies of each mutant to the wild type enzyme. The AcCoA Km value
was determined by titrating a range of AcCoA concentrations (25 µM-500 µM) into a
reaction containing 2.5 mM peptide in a buffer containing 50 mM NaCl and 200 mM
Tris, pH 8.0. The high concentration of Tris is required to counter the pH effect caused
by TFA carried into the reaction with high concentrations of peptide. A pH-rate profile
was determined using a three component buffer system able to maintain constant ionic
strength at all pH values used in the study (Tanner et al., 1999). All reactions were
performed in triplicate. All radioactive count values were converted to molar units using
a standard curve created with known concentrations of radioactive AcCoA added to
scintillation fluid.
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2.4.5 Materials and methods (‘Future directions’)
Naa50p was cloned out of the Schizosaccaromyces pombe and cloned into a
modified pCDFDUET vector with a TEV-cleavable GST-tag. The resulting plasmid was
transformed into Rosetta (DE3)pLysS competent E. coli cells (Agilent), grown to an
OD600=0.7 and induced with 0.5 mM IPTG at 16°C for ~16 hours. Cells were isolated by
centrifugation and lysed by sonication in a buffer containing 25 mM Tris (pH 8.0), 200
mM NaCl, 10 mM β-ME and 0.5mM PMSF (Sigma-Aldrich). The solution was isolated
and passed over GST-resin (GoldBio), which was subsequently washed with > 20 column
volumes of lysis buffer. TEV protease was added directly to protein-bound resin for 14
hours under gentle agitation. The resin was then washed with 5 CV of lysis buffer to
remove all cut protein and dialyzed into a buffer of 25mM Bis-Tris (pH 6.0), 0mM NaCl
and 2 mM DTT for 3-8 hours and loaded onto a 5 mL HiTrap SP ion exchange column
(GE Healthcare). Protein was eluted from the column using a salt gradient from 0750mM NaCl over 30 CV in 25mM Bis-Tris and 2mM DTT. Peak fractions were
concentrated to ~1-2 mL (10kDa concentrator; Amicon Ultra, Millipore), mixed with
purified NatA complex (for purification, see Chapter 3 ‘Materials and methods’) in a 4:1
(Naa50p:NatA complex) molar ratio, and loaded onto an s200prep gel filtration column
(GE Healthcare) that was pre-equilibrated in a buffer containing 25 mM HEPES (pH
7.0), 200 mM NaCl and 2 mM DTT. The elution profile shows 2 peaks, the first
corresponding to the NatANaa50p complex and the second corresponding to excess
Naa50p. The NatANaa50p complex was pooled and concentrated to 10 mg/mL as
measured by UV280 absorbance (extinction coefficient = 115,000), for crystallization
trials.
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NatANaa50p was mixed with 6-fold molar excess of AcCoA and crystal hits
were obtained at 20°C using hanging drop vapor diffusion in a well condition containing
18% PEG 3350 (Hampton Research) and 0.2 M sodium citrate tribasic dihydrate
(Hampton Research). To optimize, concentrations of protein and PEG 3350 were varied
and several different buffers at various pH values were added to the well. The best
crystals show diffraction to ~15 Å at NSLS and the data cannot be indexed.
For GST pull-downs assays, GST-Naa50p was left immobilized on the resin after
the wash step in the purification described above, and NatA or Naa10p (purifications
described in Chapter 3 ‘Materials and methods’) equilibrated in lysis buffer were passed
over the column five times. The column was then eluted using 5 CV of lysis buffer
supplemented with 10 mM glutathione. Control experiments were performed using GSTbound resin (GST protein was a gift from Daniel B.P. Ricketts).

2.5 Future directions and preliminary NatANaa50p complex studies
The association between Naa50p and the NatA complex is not well understood.
Naa10p and Naa15p immunoprecipitation experiments have been used to show that the
NatA complex is stoichiometrically associated with the Naa50p enzyme in both yeast and
human cell lysates (Arnesen et al., 2006a; Gautschi et al., 2003). While these reports
suggest that Naa50p interacts with the Naa15p auxiliary subunit, the potential for Naa10p
to play a role in this interaction cannot be ruled out.

It is also unclear why the

independently active Naa50p enzyme associates with the NatA complex. Preliminary
experiments (waiver:

experiments performed by my rotating students) suggest that
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complex formation has no effect on the kcat or Km exhibited by the Naa50p enzyme
towards its biologically relevant substrate. It is possible that Naa50p uses complex
formation solely for recruitment to the ribosome or that complex formation is required to
activate Naa50p towards a subset of substrates that has not yet been identified. To probe
these outstanding questions, we have set out to biochemically and structurally
characterize the Naa50pNatA complex.
Our structural characterization of NatA shows that the enzyme wraps completely
around the Naa10p subunit and no unambiguous secondary catalytic subunit-binding
interface can be identified.

To verify that Naa50p indeed interacts with the NatA

complex and does not compete with Naa10p for binding to Naa15p, we mixed untagged
NatA with immobilized GST-Naa50p and showed that GST-Naa50p is able to pull down
both the Naa10p and the Naa15p subunit (Figure 2.7A). Additionally, we were able to
show that GST-Naa50p is unable to pull down monomeric Naa10p (Figure 2.7B)1. This
series of pull-downs confirms that the Naa50p is not competing with the Naa10p subunit
for binding to Naa15p and verifies that there is an independent Naa50p binding surface
on the NatA complex. While we can conclude that Naa50p is not interacting with
monomeric Naa10p in vitro, we cannot conclude that this subunit is completely
uninvolved in the Naa50p interaction in the context of the NatA complex due to our
observation that the Naa15p subunit alters the fold of the Naa10p subunit. To further
characterize this interaction, we have also crystallized the Naa50pNatA complex for x-

1

An identical experiment with Naa15p could not be performed due to instability of this
subunit in its monomeric form.
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ray diffraction studies (Figure 2.8A). Currently, these crystals diffract poorly and
optimization of protein constructs and crystallization conditions is ongoing (Figure 2.8B).
Ideally, this study would be used to guide mutagenesis targeted at disrupting the
Naa50pNatA interface. We could use these mutants to further analyze the effect of
complex formation on catalysis and use in vivo experiments to determine the role of
complex formation in co-translational acetylation by this enzyme.
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Figure 2.7 Naa50p interacts with the NatA complex in vitro. (A) GST-tagged Naa50p
mixed with the untagged NatA complex and purified using GST resin. (B) GST-tagged
Naa50p mixed with untagged Naa10p and purified using GST resin. (C) GST mixed
with untagged NatA complex and purified using GST resin.
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Figure 2.8 NatA•Naa50p crystals and preliminary diffraction. (A) Crystals of the
NatANaa50p complex. (B) Preliminary diffraction pattern of the crystals shown in (A).
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CHAPTER 3

The molecular basis for amino-terminal acetylation by the NatA complex

Liszczak et al., 2013 (submitted)
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3.1 Introduction and summary of conclusions
Despite the fact that NATs as well as many other lysine side-chain
acetyltransferases require binding partners for optimal catalytic activity, no
acetyltransferase has been structurally characterized in the presence of its activating
partner (Iizuka and Stillman, 1999; Parthun et al., 1996; Sutton et al., 2003).
Furthermore, there is no structural data for any integral subunit of a NAT complex and
the mechanism of catalysis employed by these enzymes remains completely
uncharacterized. In this study we set out to determine the molecular basis for substrate
binding, acetylation specificity and mode of catalysis of the NatA complex, and to
determine the role of the auxiliary subunit in these activities.
Here, we report the x-ray crystal structure of the active 100 kDa holo-NatA
complex from Schizosaccharomyces pombe in the absence and presence of a bisubstrate
peptide-CoA conjugate inhibitor at 3.15 Å and 2.60 Å resolution, respectively, as well as
the structure of the uncomplexed Naa10p catalytic subunit at 2.00 Å resolution. The
Naa15p auxiliary subunit contains 13 TPR motifs and adopts a ring-like topology that
wraps completely around the Naa10p subunit. This interaction alters the Naa10p active
site for substrate-specific acetylation such that a key catalytic residue would be displaced
upon interaction with a non-cognate substrate peptide. The bisubstrate peptide-CoA
conjugate NatA inhibitor that we developed also lays the foundation for the development
of potent and selective NatA therapeutics. These studies have important implications for
understanding the activity and regulation of other NAT complexes and for how
regulatory subunits modulate the activity of the broader family of protein
acetyltransferases.
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3.2 Results
3.2.1 Overall structure of the NatA complex
In an attempt to prepare the NatA complex for x-ray structure determination, we
overexpressed the human complex in Sf9 infected insect cells and the othologous proteins
from Saccharomyces cerevisiae and Schizosaccharomyces pombe in insect cells and
bacteria, respectively. We found that coexpression of the Schizosaccharomyces pombe
full-length Naa15p subunit (residues 1-729) with a C-terminal truncation construct of the
Naa10p subunit (residues 1-156 out of 177 total residues) produced a soluble, active,
heterodimeric complex that could be purified to homogeneity and crystallized for use in
structural studies. Crystals of this NatA complex were formed in the presence of AcCoA
in the P1 space group with 4 heterodimers in the asymmetric unit and the structure was
determined using multiwavelength anomalous diffraction with a combination of a
K2PtBr4 heavy atom soaked crystal and selenomethionine-derivatized protein (Table 3.1).
The dataset was refined to Rwork and Rfree values of 22.4% and 25.9%, respectively.
The structure of the NatA complex reveals that the auxiliary Naa15p subunit is
composed of 37 α-helices ranging from 8 to 32 residues in length, among which 13 well
conserved helical bundle tetratricopeptide repeat (TPR) motifs can be identified, which
are often employed for protein-protein interactions (Figures 3.1 and 3.2).

While a

number of these TPR-helices are involved in interaction with Naa10p, we suspect that the
additional TPR motifs are important for interaction with other NatA binding partners
such as the ribosome, NatE and the HYPK chaperone (Arnesen et al., 2010; Gautschi et
al., 2003). The Naa15p helices arrange themselves into a ring-like tertiary structure that
wraps completely around the Naa10p subunit, burying a total of 3,520 Å 2 of the solvent
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accessible surface area of the enzyme (Figure 3.3A and 3.3B). This fold is reminiscent
of the importin-β structure, which employs 19 tandem HEAT repeats to form a solenoid
tertiary structure that surrounds its binding partner, importin-α (Cingolani et al., 1999).
Indeed, it appears that Naa15p stability depends on the binding of Naa10p. This is
consistent with the observation that recombinant Naa15p undergoes significant
degradation and precipitation when purified as a monomer.
The catalytic Naa10p subunit adopts a Gcn5-related N-acetyltransferase (GNAT)
fold (Vetting et al., 2005) containing a central AcCoA binding region and flanking Nand C- terminal segments that are similar to the structure of NAA50. The most intimate
interactions between the two proteins are made between several Naa15p helices and the
N-terminal α1-loop-α2 segment of Naa10p (Figures 3.3C and 3.3D), where the structure
has relatively low B-factors and is well ordered (Figures 3.4A and B). This region
features one large hydrophobic interface between residues that span the entire length of
Naa10p-α2 (L28, L32, Y33, I36, W38) and several residues of Naa10p-α1 (I8 and L11)
with residues in Naa15p-α29 (W526, F533, F536) and –α30 (L549, W552); and hydrogen
bonds between Naa10p-K29 and Naa10p-Q15 with Naa15p-D532 and Naa15p-Q491,
respectively. Single point mutations in this region do not break up the complex, and have
only modest effects on substrate binding and catalysis (Table 3.2), likely due to the
extensiveness of the interface.

A smaller hydrophobic interface is formed between

Naa10p-H20 with Naa15p-F449 and Naa15p-W494 and is supplemented with a hydrogen
bond between Naa10p-N25 and Naa15p-R448. This region of Naa15p directly stabilizes
the position of the Naa10p-α1 helix as well as the Naa10p-α1-α2 loop and as a result is
crucial for proper complex formation. This is evident from the observation that alanine
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point mutations at either Naa15p-R448 or Naa15p-F449 disrupt NatA complex
formation. Several additional scattered intermolecular interactions serve to supplement
the Naa10p-Naa15p interface (Figure 3.5).
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Table 3.1 Data collection, phasing and refinement statistics

Values in parentheses are for the highest resolution data shell. Rfree was calculated using
5% of the reflection data and omitted at the start of refinement. r.m.s.d., root mean
standard deviation; DM, density modification; A.U., asymmetric unit.
*These two chains make up the heterodimer with the lowest average B-factor in the
AcCoA and bisubstrate inhibitor-bound complexes. All figures were generated using
these heterodimers.
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Table 3.2 Catalytic parameters for wild type and mutant NatA as well as wild type
monomeric Naa10p with various substrate peptides

The kcat and Km for all catalytic assays performed are given. Where kcat=N/A, the Km is
greater than 2,000 μM and as a result a rate could not be calculated from our assay.
Where kcat=N.D., activity could not be detected in our assay.
+
All normalizations reported are relative to wild type NatA catalytic parameters
generated with the Ser- amino-terminal substrate.
*The AcCoA Km was calculated for these variants (WT=59±5 μM, L22A=53±6 μM).
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Figure 3.1 TPR repeats in Naa15p. (A) The helices that make up each TPR repeat are
colored in alternating dark blue and light blue and the first helix of each repeat is
numbered. All other Naa15p helices are shown in brown cartoon format and the N and
C-termini are labeled. Naa10p is shown in teal cartoon format and AcCoA is shown in
blue stick format. (B) Same as (A) but rotated 180°. All observed TPR repeats match the
known TPR motif divergent consensus sequence (Karpenahalli et al., 2007).
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Figure 3.2 Conservation across Naa15p subunits. (A) The Naa15p is shown in
surface representation with residues colored according to conservation exhibited in an
alignment of corresponding subunits in S. pombe, H. sapiens, A. thaliana, S. cerevisiae,
C. elegans and D. melanogaster. The key provided indicates the level of conservation
represented by each color. Naa10p is shown in teal cartoon format and AcCoA is shown
in blue stick format. (B) Same as (A) but rotated 180°. No unambiguous putative
ribosomal binding surface can be identified from this conservation map.
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Figure 3.3 The overall structure of the NatA complex bound to AcCoA. (A) The
Naa10p (teal) and Naa15p (brown) subunits are shown in cartoon bound to AcCoA (CPK
coloring and stick format). Only Naa15p helices that contact Naa10p are labeled. The
dotted brown line represents a disordered loop region in Naa15p. The dimensions of the
complex are 107 Å x 85 Å x 70 Å. (B) A 90° rotation of the view in (A). (C) A zoom
view highlighting key residues that comprise the mostly hydrophobic interface between
Naa10p-α1-α2 and Naa15p-α29-α30.

(D) A zoom view of the intersubunit interface at

the C-terminal region of Naa10p-α1 and Naa15p helices.
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Figure 3.4 Average B-factor distribution. (caption on following page)
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Figure 3.4 (continued) (A) The average B-factor for each helix and loop in Naa15p
(cartoon format) is colored according to the key provided. Naa10p is shown in teal
cartoon format and the AcCoA is shown in blue stick format. All visible helices from
each subunit are labeled, as are the N and C-termini of Naa15p. (B) Identical to (A) but
rotated 90°. Helices not labeled in (B) are labeled here. (C) The average B-factor for
each helix, strand, and loop in Naa10p (cartoon format) is colored according to the key
provided. Naa15p is represented in brown cartoon format and AcCoA is shown in blue
stick format. All helices in Naa10p are labeled. (D) Identical to panel (C) but rotated
90°. Naa15p helices α23 though α32 have been omitted for clarity. Only N and Cterminal helices from Naa15p are labeled.
*The α20-α21 loop has an average B-factor of 196 Å2 (see supplemental text for
explanation).

65

Figure 3.5

Additional contacts at the Naa10p•Naa15p interface.

following page)
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(caption on

Figure 3.5 (continued) (A) A full view of the complex with Naa10p shown in teal
cartoon format, Naa15p shown in brown cartoon format, and AcCoA shown in blue stick
format.

A region in which intermolecular contacts are formed has been boxed.

Secondary structure elements visible in the corresponding zoom view are labeled. The N
and C-termini of Naa15p are labeled. (B) Identical to (A) but rotated 90°. (C) A zoom
view of the boxed region in (A). Residues involved in intermolecular contacts are shown
in stick format and all secondary structure elements are labeled. Hydrogen bonds are
shown with black dotted lines. (D) A zoom view of the boxed region in (B). Residues
involved in intermolecular contacts are shown in stick format and all secondary structure
elements are labeled. Hydrogen bonds are shown with black dotted lines.
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3.2.2 Structure of uncomplexed Naa10p subunit and the molecular basis for Naa15p
modulation of Naa10p acetylation
To explore the molecular basis for Naa15p modulation of Naa10p
acetyltransferase activity, we determined the X-ray crystal structure of Naa10p in the
absence of Naa15p, for comparison with the holo-NatA complex (Table 3.2).

The

structure of Naa10p (residues 1-156) was determined using a combination of single
wavelength anomalous diffraction and molecular replacement (MR), using data collected
on a selenomethionine-derivatized Naa10p protein and NAA50 as an MR model. An
alignment of the complexed and uncomplexed forms of Naa10p reveals that the α1-loopα2 segment assumes a substantially different conformation in the presence of Naa15p
(Figure 3.6A). Notably, this conformational change is driven by the movement of several
hydrophobic residues in Naa10p-α2 (L28, L32, I36), which make intramolecular
interactions with residues in Naa10p-α1 and β3 (I8, L11, M14, Y55, Y57) in apo-Naa10p
but shift to make alternative intermolecular interactions with helices of Naa15p in the
NatA complex (Figure 3.6B and 3.3C). As a result of this interaction, the C-terminal
region of the α1 helix undergoes an additional helical turn, which helps to reposition the
α1-α2 loop. Interestingly, docking of the apo-Naa10p structure into the corresponding
binding pocket of Naa15p shows a clash between the Naa10p α1-loop-α2 and Naa15pR448 and Naa15p-F449 of α25 (Figure 3.6C), the same interface that we have shown to
be necessary for proper complex formation (Fig. 3.3D, Table 3.2).
As a result of the Naa15p-interaction along one side of the Naa10p-α1-loop-α2
region, residues on the opposite side of this loop region appear to adopt a specific
conformation that is essential for catalysis towards traditional substrates (Ala-, Cys-,
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Gly-, Ser-, Thr-, or Val-). Specifically, residues Naa10p-L22 and -Y26 shift about 5.0 Å
from surface exposed positions to buried positions in the active site and Naa10p-E24
moves by about 4.0 Å, drastically altering the landscape of the NatA active site (Figure
3.6D). All of these residues are well ordered in both structures (Figures 3.7A and 3.7B).
Our comparison of the complexed and uncomplexed structures suggests that the auxiliary
subunit induces an allosteric change in the Naa10p active site to an extent that is required
for the mechanism of catalysis employed by the NatA complex, and likely represents an
active NAT fold. Consistent with this hypothesis, a backbone alignment of key active
site elements in active Naa10p with the corresponding region in the independently active
human NAA50 that selects a Met-Leu- amino-terminal sequence shows a high degree of
structural conservation (RMSD of 1.52 Å).

The corresponding alignment of the

complexed and uncomplexed forms of Naa10p shows less structural conservation, with
an RMSD of 2.43 Å (Figure 3.6E).
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Figure 3.6 The structure of the Naa10p monomer bound to AcCoA. (caption on
following page)
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Figure 3.6 (continued) (A) A structural backbone alignment of the uncomplexed Naa10p
monomer (silver) bound to AcCoA (gray stick format) with the active Naa10p from the
NatA structure (teal). (B) A zoom view of the surface exposed Naa10p-α1-α2 region
from the alignment shown in A highlights residues in these two helices that undergo a
conformational shift upon Naa15p association. (C) The Naa10p variants docked into the
Naa15p subunit. The stretch of the α1- α2 loop in the Naa10p monomer that clashes with
Naa15p is shown in the zoom region. Secondary structural elements are shown in
cartoon format and have been labeled. Key residue side chains are shown in stick format
and have been labeled. (D) A 70° clockwise rotation of B. The repositioning of the
Naa10p-α1-loop- α2 upon complex formation and accompanying altered active site
landscape are shown.

Key repositioned residues are shown in stick format. (E) A

structural alignment of the active and inactive forms of Naa10p with hNaa50p (red)
bound to CoA (gray stick format).
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Figure 3.7 Naa10p substrate binding loops with corresponding electron density.
(A) The α1-α2 and β6-β7 loop from the Naa10pNaa15pbisubstrate inhibitor structure is
shown with corresponding simulated annealing composite omit map contoured to 1.5σ
(shown in blue). Loop backbones are labeled and shown in teal cartoon format and side
chains are labeled and shown in teal stick format. The bisubstrate inhibitor is shown in
orange stick format and the residues have been numerically labeled. (B) The α1-α2 and
β6-β7 loop from the Naa10p monomeric structure is shown with corresponding simulated
annealing composite omit map contoured to 1.5σ. Loop backbones are labeled and
shown in silver cartoon format and side chains are labeled and shown in silver stick
format. AcCoA is shown in gray stick format.
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3.2.3 Substrate peptide binding and NatA inhibition
To determine the molecular basis for substrate-specific peptide-binding by NatA,
and in particular how, unlike most other NATs, it is able to accommodate a number of
non-methionine amino-terminal substrates, we synthesized a bisubstrate conjugate in
which CoA is covalently linked to a biologically relevant substrate peptide fragment with
the sequence Ser-Ala-Ser-Glu-Ala (CoA-SASEA). We performed inhibition studies with
CoA-SASEA and with a control compound, acetonyl-CoA, which is a non-hydrolyzable
AcCoA analog (Fig. 3.8A). IC50 determinations revealed that CoA-SASEA had an IC50
of 1.4±1.0 µM, while acetonyl-CoA had an IC50 of 380±10 µM (Fig. 3.8B). To assess
the specificity of this inhibitor towards NatA, we also calculated IC50 values of CoASASEA and acetonyl-CoA with NAA50, a NAT that requires a substrate amino-terminal
methionine residue. We found that CoA-SASEA has an IC50 of 11±2 µM while acetonylCoA has an IC50 of 130±12 µM (Fig. 3.8B). With NAA50, the addition of a SASEApeptide portion is only able to increase the potency of acetonyl-CoA 12-fold, whereas
with NatA this peptide addition exhibits a 271-fold increase in potency. The greater
potency of acetonyl-CoA with NAA50 over Naa10p can be explained by the fact that
AcCoA binds more strongly to NAA50 (Km=27±2 µM) than it does to Naa10p (Km=59±5
µM). The significantly higher potency of the CoA-SASEA inhibitor relative to acetonylCoA towards NatA, along with the observed NatA specificity that the peptide portion
imparts on the inhibitor, suggest that CoA-SASEA serves as a suitable transition state
mimic for use in understanding the molecular basis for amino-terminal substrate binding
by NatA.
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We were able co-crystallize NatA bound to CoA-SASEA and determine its x-ray
crystal structure using the refined NatA•AcCoA structure as a search model (Table 3.1
and Fig. 3.9A). The structure of the bisubstrate inhibitor-bound NatA complex reveals
that the N-terminal Ser1 side chain makes van der Waals interactions with Naa10p
residues L22, E24 and Y139 (Fig. 3.9B). The Naa10p-Y139 side chain also forms a
hydrogen bond with the Ser1 backbone carbonyl group, and Naa10p-Y26 forms a
hydrogen-bond with the Ala2 backbone carbonyl.
We used in vitro activity assays to kinetically characterize the wild type Naa10p
monomer enzyme as well as wild type NatA and a series of NatA mutants (Table 3.2).
These assays were performed in the presence of a substrate peptide with an aminoterminal sequence identical to that of the inhibitor, a Met- amino-terminal substrate
peptide that corresponds to the NAA50 in vivo substrate, and a substrate peptide with an
amino-terminal Glu-Glu-Glu- sequence that matches the sequence for γ-actin, the only
known NAA10 in vivo substrate. These studies revealed that while monomeric Naa10p is
inactive with the Ser- amino-terminal substrate, we are able to generate catalytic
parameters with the Glu- amino-terminal substrate (kcat=0.19 ± 0.02 sec-1; Km=1.72 ±
0.25 μM) (Table 3.2). While previous studies were able to detect acetylation of the
amino-terminal Glu- substrate by the NatA complex (Van Damme et al., 2011a), we were
unable to detect activity towards this substrate. In contrast, we were able to determine
kinetic parameters for the Ser- amino-terminal substrate in the presence of a saturating
amount of AcCoA (kcat=3.0±0.5 s-1 and Km=340±50 μM). The NatA-Naa10p-L22A point
mutation exhibited a 209-fold decrease in catalytic efficiency (kcat/Km), suggesting that
steric alterations to the amino-terminal residue-binding pocket greatly hinders productive
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substrate binding and catalysis (Figure 3.10 and Table 2). Similarly, the NatA-Naa10pE24A mutant had no measurable activity. The kcat of the NatA-Naa10p-E24Q was
significantly reduced by a factor of 120 while the Km was unaffected, which emphasizes
the importance of E24 in both substrate binding and catalysis (Table 3.2). The NatANaa10p-Y26A mutant resulted in a 144-fold decrease in catalytic efficiency, while the
catalytic efficiency for the NatA-Naa10p-Y139A mutant could not be calculated due to
the immeasurably high Km (Table 3.2), which is likely caused by the fact that Y139 is
involved in both a backbone interaction and the Ser1 side chain-binding pocket. To
evaluate the active site of the uncomplexed Naa10p, we docked the bisubstrate inhibitor
into the monomeric structure that is inactive towards the amino-terminal Ser- substrate.
Consistent with the particular importance of Naa10p residues L22, E24, Y26 and Y139 in
NatA catalysis of traditional substrates, each of these residues are not in a position for
productive substrate binding and catalysis in uncomplexed Naa10p, with the exception of
Y139 (Figure 3.9C).
Although all of the important catalytic residues noted above for NatA catalysis of
the Ser-amino terminal substrate appear out of place for catalysis by the Naa10p
monomer, it is able to catalyze acetylation of the Glu-amino-terminal substrate,
suggesting that the acetylation reaction by Naa10p is catalyzed through an alternate
mechanism relative to that of the NatA complex. To investigate the possibility that the
Glu-amino-terminal substrate substrate does not require the E24 catalytic residue for
acetylation, we performed an assay using this substrate and the NatA-E24A mutant. This
mutant, which we found will not acetylate the amino-terminal Ser- or Met- aminoterminal substrates used in this study, is able to acetylate the Glu- amino-terminal
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substrate with a rate that is only 4.5-fold slower than the rate of the wild type NatA
complex with its cognate Ser-amino terminal substrate peptide (Table 3.2). We suspect
that the more open amino-terminal residue-binding pocket is able to accommodate an
amino-terminal Glu- substrate peptide and that the carboxylic acid group of the Glu1 side
chain occupies a position that is very similar to the corresponding group in the wild type
NatA-E24 side chain; consequently, it seems to be able to play an equivalent role in
catalysis.

The recovery of activity observed when using this substrate-mutant

combination further supports the importance of the E24 carboxylic acid moiety in the
NatA catalytic mechanism.
To determine the molecular basis for the inability of NatA to acetylate N-terminal
methionine and glutamate residues, we modeled an amino-terminal glutamate residue and
docked the human NAA50 substrate into the active Naa10p site (Figure 3.9D). This
superposition revealed that Naa10p-E24 would clash with the substrate peptide
methionine residue, suggesting that Naa10p-E24 is particularly important for excluding
N-terminal methionine substrates.

This is consistent with the importance of the

corresponding human Naa50-V29 residue for N-terminal methionine recognition and
acetylation (Liszczak et al., 2011). We also modeled substrate amino-terminal Thr- and
Val- residues, the most bulky NatA substrates, into the active site to show that these side
chains can also be accommodated without steric clash in the wild type NatA substratebinding pocket (Figure 3.9D).
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Figure 3.8 Inhibitor structures and IC50 curves. (A) A ChemDraw representation of
CoA is shown along with R-groups that correspond to the structure of AcCoA, acetonyl
CoA and the bisubstrate inhibitor (SASEA-CoA). (B) The dose response curves
corresponding to the titration of SASEA-CoA and acetonyl CoA into a wild type
Naa10pNaa15p acetyltransferase reaction and a wild type hNaa50p acetyltransferase
reaction. IC50 values for each inhibitor are also shown.
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Figure 3.9 Structure of the NatA complex bound to a bisubstrate inhibitor. (caption
on following page)
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Figure 3.9 (continued) (A) The structure of the bisubstrate inhibitor (orange) as it
appears when bound to Naa10p in the context of the NatA complex. A simulated
annealing omit map contoured to 1.5σ is shown in blue. Peptide residues are numbered
relative to their position in the sequence. (B) A zoom view of the active site of the
Naa10p enzyme bound to the inhibitor. Residues that interact with the substrate peptide
regions are shown in stick format and hydrogen bonds are shown as black dotted lines.
(C) A model of the inhibitor docked into the inactive form of Naa10p. Corresponding
residues of the inactive Naa10p structure that mediate substrate interactions in the active
Naa10p form of the enzyme are shown in stick format. (D) A model of the human
Naa50p substrate and CoA (yellow stick format) docked into the active site of the
complexed Naa10p. Glutamate (silver), valine (green) and threonine (blue) substrate
amino-terminal side chains have been docked into the peptide-binding pocket. Residues
from each enzyme that have been shown to interact with their corresponding substrate
peptides are shown in stick format.
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Figure 3.10 Catalytic characterization of key NatA mutants. A bar graph showing
the catalytic efficiencies of key point mutants.
N/A = This mutant has a Km greater than 2,000 μM and catalytic efficiency cannot be
calculated.
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3.2.4 Catalysis by NatA
Previous structural and kinetic studies on human NAA50 support a dual base
mechanism in which NAA50-Y73 and -H112, located in the central core region and Cterminal segment of the catalytic domain, contribute to proton abstraction from the
substrate α–amino group to facilitate the acetylation reaction (Liszczak et al., 2011). An
active site alignment of these enzymes shows that Naa10p also has two potential general
bases in corresponding positions, Naa10p-H72 and -H111 (Figure 3.11A). However,
point mutations of H72A (kcat = 2.4±0.3 sec-1) and H111A (kcat = 2.0±0.2 sec-1) each had
a negligible effect on the rate of catalysis, arguing against the importance of these
residues in catalysis by Naa10p (Table 3.2). Notably, NAA50 also has a water molecule
in the active site that is likely to play a catalytic role, which is not observed in the Naa10p
active site and further supports the idea that NatA employs a different catalytic
mechanism (Liszczak et al., 2011).
The NatA structures reveal that E24, located in the loop between the α1 and α2
helices in the N-terminal segment of the Naa10p catalytic domain, is in close proximity
to the amino-terminal residue and could be playing a role in catalysis (Figure 3.11A).
This is consistent with our observation that the E24Q mutant shows a 120-fold reduction
in kcat and has a negligible effect on Km , which suggests that the carboxylic acid moiety
is essential for catalysis, but not required for substrate binding (Table 3.2). In both Gcn5
and ESA1, mutating the general base glutamate to a glutamine also results in a decrease
in kcat by ~2 orders of magnitude, which supports the possibility that Naa10p-E24 of
NatA could be acting as a general base in the NatA acetylation reaction(Berndsen et al.,
2007; Tanner et al., 1999), whereby the buried glutamate residue harbors an increase in
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side chain pKa that allows it to directly deprotonate the substrate amino group.
Alternatively, the glutamate residue could act through an electrostatic mechanism causing
an induced-dipole on the α-amino group that would increase the nucleophilicity of the
substrate. While NatA-Naa10p-E24 functions as an essential catalytic residue, it is also
possible that NatA-Naa10p-Y139, located in the C-terminal segment of the Naa10p
catalytic domain, also contributes to catalysis due to its location in the active site and the
dramatic effect on catalysis observed for the NatA-Naa10p-Y139A mutant. Significantly,
NatA-Naa10p-R113, also in this C-terminal segment, forms an ionic interaction with
E24.

An observed 18-fold reduction in catalytic efficiency for the Naa10p-R113A

mutant suggests that this residue may also be important for proper positioning of the
Naa10p-E24, altering the pKa of the E24 side chain, or it may have some other function
in the NatA catalytic mechanism or substrate binding/positioning. A comparison of the
catalytic efficiencies of potential key catalytic residues is shown in Figure 3.10. A
sequence alignment of the Naa10p catalytic subunits from a diverse group of eukaryotic
species reveals that all of the α1-α2 loop residues, as well as R113 and Y139, are strictly
conserved, which reinforces the importance of these residues in catalysis (Figure 3.11B).
To further dissect the reaction mechanism, we also calculated Ki values of the
CoA-SASEA inhibitor as well as its mode of inhibition towards both AcCoA and the
substrate peptide.

Our results (Figure 3.12A-D) reveal that the CoA-SASEA is a

competitive inhibitor versus AcCoA (Ki=1.1±0.1 μM) and a noncompetitive inhibitor
versus the substrate peptide (Ki=8.9±0.1 μM). This pattern of inhibition supports an
ordered BiBi model for catalysis, with AcCoA binding occurring before the substrate
peptide (Copeland, 2005).

This type of mechanism was also recently reported for
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NAA50 in a study that used NMR experiments to show that AcCoA binding induces
rearrangements in the peptide-binding pocket and that the peptide shows a far greater
affinity toward the NAA50•AcCoA complex over the apo enzyme.
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Figure 3.11 The active site of the NatA complex and other GNAT
acetyltransferases. (caption on following page)
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Figure 3.11 (continued) (A) The active site of the inhibitor-bound Naa10p subunit. The
inhibitor (orange) and residues found to be important for catalysis (teal) are shown in
stick format.

The general bases of the hNAA50 enzyme (pink) and corresponding

residues in Naa10p are also shown in stick format. (B) Sequence alignment of key
features from Naa10 catalytic subunits from Schizosaccharomyces pombe (Sp),
Arabidopsis thaliana (At), Caenorhabditis elegans (Ce), Candida albicans (Ca),
Drosophila melanogaster (Dm), and Homo sapiens (Hs). Black circles () have been
placed above proposed key catalytic residues and crosses (+) have been placed above
proposed substrate binding residues. (C) Alignment of the NatA active site with the
corresponding active sites of other protein and small molecule GNAT enzymes. Key
catalytic residues for each enzyme are highlighted. (D) Sequence alignment of catalytic
subunits of NAT complexes from . Black circles () have been placed above proposed
key catalytic residues and crosses (+) have been placed above proposed substrate binding
residues Schizosaccharomyces pombe (Sp) and Homo sapiens (Hs).
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Figure 3.12 Bisubstrate inhibition studies. (A) Michaelis-Menton plots for Naa10p in
the presence

of various concentrations of AcCoA (0-500 μM)

with inhibitor

concentrations ranging from 0-15 µM. Best fit data corresponds to a competitive mode
of inhibition (Ki = 1.1±0.1 μM). (B) Michaelis-Menton plots in the in presence of
various concentrations of substrate peptide (0-1000 μM) with inhibitor concentrations
ranging from 0-30 µM. Best fit data corresponds to a noncompetitive mode of inhibition
(Ki = 8.9±0.2 μM). (C) A Lineweaver-Burke plot corresponding to data shown in (A).
(D)

A Lineweaver-Burke plot corresponding to data shown in (B).

experimental procedures can be found in ‘Materials and methods’.
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Detailed

3.3 Discussion
The data presented here reveals that Naa15p allosterically reconfigures the
Naa10p active site for sequence-specific amino-terminal acetylation. Specifically, this
study highlights a unique mechanism in which NatA substrate binding specificity is
coupled to the catalytic strategy that is employed. This finding is supported by evidence
that an amino-terminal residue of an incompatible substrate, such as a methionine, would
have to displace E24, an essential catalytic residue, for binding to occur (Figure 3.9D).
Furthermore, upon modeling all bulky, β-branched NatA cognate substrate aminoterminal residues into the binding pocket, we find that none of them clash with the E24
residue, which further supports the importance of this residue and its role in substratespecific acetylation (Figure 3.9D).

We also note that in the absence of E24, the only

peptide we found that can still undergo acetylation is the Glu-amino-terminal substrate,
likely due to the fact that the side chain carboxylic acid moiety is able to functionally
replace the corresponding group on the E24 side chain. This could also explain the
activity observed for the Naa10p monomer in the presence of this substrate (Van Damme
et al., 2011a).
Comparison of the Naa10p active site with the corresponding region of NAA50
and other HATs shows significant differences that appear to underlie the fact that Naa15p
binding is required for Naa10p acetyltransferase activity towards conventional substrates.
In particular, three catalytically essential Naa10p residues that are located in the α1-α2
loop that is N-terminal to the catalytic core region, L22, E24, and Y26, are not correctly
positioned for catalysis in the uncomplexed form of the enzyme (Figure 3.9C).
Significantly, in the context of the NatA complex, the L22 and Y26 side chains shift from
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surface exposed positions into the active site while the E24 side chain is repositioned by
~5 Å to facilitate the observed coupling of substrate binding specificity and catalysis.
These changes in the Naa10p conformation are essential for productive catalysis of
traditional substrates. In contrast, the independently active NAA50 and other HATs have
their key catalytic residues located on the opposite side of the substrate, either within the
central core region or the segment C-terminal to the catalytic core region (Figure 3.11C).
It appears that Naa10p contains its key residues for catalysis on the opposite side of the
substrate relative to NAA50 and the other HATs to allow for catalytic regulation through
Naa15p binding.
A sequence alignment of the Naa10p catalytic subunits from a diverse group of
eukaryotic species reveals that all of the α1-α2 loop residues, as well as R113 and Y139,
are strictly conserved, which reinforces the importance of these residues in catalysis
(Figure 3.11B). In addition, based on our findings of Naa15p regulation of Naa10p
activity, we propose that the catalytic subunits of the NatB and NatC NAT complexes are
modulated for acetylation in similar ways by their auxiliary subunits. This hypothesis is
consistent with the strict conservation of the Naa10p-L22, -E24, and Y26 residues across
catalytic subunits of each of these NAT complexes (Figure 3.11D), which also reinforces
the importance of this loop for enzymatic activity of NAT enzymes. However, NatB and
NatC both acetylate methionine containing amino-terminal substrates, so these complexes
likely use other novel strategies to accommodate their respective substrates.

Many

protein lysine side-chain acetyltransferases, including HAT1 (Parthun et al., 1996),
HBO1 (Iizuka and Stillman, 1999) and Sas2 (Sutton et al., 2003), also require auxiliary
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subunits for activated acetylation and it is of significant interest to determine if they also
share similar strategies for catalytic regulation with heterodimeric NAT proteins.
The unique features of the NatA complex could be exploited for the development
of NatA-specific inhibitors. Indeed, to our knowledge, the CoA-SASEA NatA inhibitor
that we have prepared is the most potent NAT inhibitor that has been reported to date.
This inhibitor may serve as a suitable probe for NatA inhibition in vitro, and although
peptide-based inhibitors are generally not suitable inhibitors for cell-based studies due to
their poor ability to penetrate cell membranes, the CoA-SASEA inhibitor may
nonetheless serve as a starting point for the development of small molecule mimics with
better pharmacological properties.

Furthermore, our inhibition studies suggest that

inhibitors targeting the peptide-binding pocket have the potential to specifically inhibit
NatA relative to other NATs while AcCoA analogues will likely exhibit more
promiscuous inhibition patterns. Given the observations that NatA subunits are often
overexpressed in several different cancer tissues, suggests that NatA inhibitors may have
therapeutic application (Fluge et al., 2002; Kalvik and Arnesen, 2013; Lim et al., 2006;
Ren et al., 2008; Yu et al., 2009b).

3.4 Materials and methods
3.4.1 Naa10p expression and purification
The full length Naa10p gene (encoding residues 1-177) was cloned out of the
Schizosaccharomyces pombe genome (ATCC) and several C-terminal truncation
constructs were engineered into a modified pETDUET vector containing a TEV protease89

cleavable 6XHis-tag.

All constructs were transformed into Rosetta (DE3)pLysS

competent E. coli cells, grown to an OD600=0.7 and induced with 0.5 mM IPTG at 16°C
for ~16 hours. Cells were isolated by centrifugation and lysed by sonication in a buffer
containing 25 mM Tris (pH 8.0), 500 mM NaCl, 10 mM β-ME and a complete, EDTA
free protease inhibitor tablet (Roche). The solution was isolated and passed over Ni-resin
(Thermo Scientific), which was subsequently washed with > 20 column volumes of lysis
buffer supplemented with 25 mM imidazole. The protein was eluted in the same buffer
with an imidazole gradient (25-500 mM imidazole) and TEV protease was added to
fractions containing the target protein for the duration of a 14-hour dialysis into lysis
buffer. The solution was passed through an additional nickel column to remove TEV
protease as well as any uncut Naa10p. The resin was then washed with ~ 7 column
volumes of lysis buffer supplemented with 25 mM imidazole, which was pooled with the
initial flow through. This solution was dialyzed into a buffer containing 25mM sodium
citrate monobasic (pH 5.5), 100 mM NaCl and 2 mM DTT and loaded onto a 5 mL
HiTrap SP ion exchange column (GE Healthcare). The protein was eluted in the same
buffer using a salt gradient (100-750 mM NaCl). Peak fractions were concentrated to 8.0
mg/mL (10kDa concentrator; Amicon Ultra, Millipore) as measured by UV280 absorbance
(extinction coefficient = 18,000), for crystallization trials.

The selenomethionine

derivative was prepared by expressing Naa10p (residues 1-156) in minimal medium
(Molecular Dimensions) containing 50 μg/L of selenomethionine (Sigma), which was
purified using the scheme described above.
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3.4.2 Naa10pNaa15p complex expression and purification
The full length Naa15p gene (encoding residues 1-729) was cloned out of the
Schizosaccharomyces pombe genome and engineered into MCSI of a modified
pETDUET vector containing a TEV protease-cleavable 6XHis-tag.

DNA encoding

residues 1-156 of Naa10p was engineered into MCSII of the corresponding vector. Cells
were grown and the binary protein complex was prepared essentially as described for
Naa10p, except that the first of two peaks that eluted from the HiTrap SP ion exchange
column was concentrated to 1mL, and loaded onto an s200prep gel filtration column (GE
Healthcare) in a buffer containing 25 mM HEPES (pH 7.0), 200 mM NaCl and 1 mM
TCEP. This protein was concentrated to 15 mg/mL as measured by UV280 (extinction
coefficient = 100,000) for crystallization trials. The selenomethionine labeled complex
was obtained in as described above. Point-mutation proteins were generated using the
Stratagene QuikChange protocol and protein harboring point mutations was expressed
and purified using the protocols described above (Braman et al., 1996).

3.4.3 Naa10p crystallization and structure determination
Naa10p at a concentration of 8 mg/mL was mixed with AcCoA at a 1:3 molar
ratio. Initial crystallization hits were obtained from an Naa10p construct containing
residues 1-161 (Naa10p (1-161)) using hanging drop vapor diffusion at 20°C with a well
solution containing 16% PEG 8000 (Hampton Research), 10% ethylene glycol and 0.1M
HEPES (pH 7.5) and yielded poor diffraction. These crystals were used to seed entire
grid screens with Naa10p(1-156), which did not crystallize in the absence of the seed
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crystals.

Large crystals of Naa10p(1-156) were obtained from this screen in a 1:1

mixture of protein and well solution (14% PEG 3350 and 0.1M bis-tris (pH 6.5)) using
hanging drop vapor diffusion at 20°C. An additive screen (Hampton Research) revealed
that these crystals could be reproduced in the absence of seed crystals when 10% glycerol
was present as an additive in the crystallization drop. Final crystallization conditions of
the Naa10p protein (construct 1-156) were optimized and include a drop with a
2.5:0.5:2.0 ratio of protein (8 mg/mL): glycerol (50%): well solution, mixed in that order.
Selenomethionine crystals of this construct were obtained using identical conditions with
a lower protein concentration (6.5 mg/mL). Diffraction quality crystals required 1-3 days
to grow to maximum dimensions.
Datasets were collected at beamline X29A at the National Synchrotron Light
Source (Brookhaven National Laboratory) processed using HKL2000 (Otwinowski and
Minor, 1997).

Initial molecular replacement trials with the program Phaser were

performed using several truncated variants of the hNaa50p structure (PDB ID: 3TFY) as
a model, but were unable to provide electron density maps suitable for model building
(McCoy et al., 2007). A dataset was then collected on the selenomethionine-labeled
protein at the selenium peak wavelength (0.9795Å) but selenium sites could not be
identified using single wavelength anomalous diffraction (SAD) or single isomorphous
replacement with anomalous scattering (SIRAS). The selenium sites were located by
performing molecular replacement (as described above) on the selenomethionine
derivative dataset, contouring the output electron density map to 3.0σ, and placing
selenium atoms at the resulting peaks in Coot (Emsley and Cowtan, 2004). These sites
were input into Phaser along with the hNaa50p model, and an MR-SAD approach yielded
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high quality electron density maps.

Initial model building was carried out using

ARP/wARP and refinement was carried out using Phenix.refine (experimental phases
excluded throughout refinement) while applying 2-fold NCS (Adams et al., 2010; Langer
et al., 2008). TLS was used in later stages of refinement (TLS groups defined using the
open access server) (Painter and Merritt, 2005, 2006). Manual refinement and additional
model building were performed using the program Coot.

The selenomethionine

containing crystals diffracted to a higher resolution (2.00 Å) than the wild type crystals
(2.60 Å) and so the structure used in all analyses was that of the SeMet-derivatized
protein. The final model was checked for errors using a composite omit map generated
by AutoBuild in the Phenix suite of programs (Adams et al., 2010).

3.4.4 Naa10pNaa15p crystallization and structure determination
The Naa10p (1-156)Naa15p (full length) complex was concentrated to 12
mg/mL and mixed with 3X cofactor (AcCoA or bisubstrate inhibitor) and allowed to
stand for 12-15 hours at 4°C. The initial crystallization hit was obtained using hanging
drop vapor diffusion at 20°C in a well solution containing 10% PEG 4000, 10%
isopropanol and 0.1M HEPES (pH 7.0) (all reagents from Qiagen). The best crystals
were obtained by mixing protein:well at a 2.0μL:2.0μL ratio and grew to maximum
dimensions in 7-10 days.

These crystals were transferred into mother liquor

supplemented with ethylene glycol in 5% increments (15%, 20%, 25%) for 1 minute at
each concentration and finally flash-frozen in liquid nitrogen. The selenomethioninelabeled protein required that the protein buffer be supplemented with 1mM reduced L93

Glutathione and 1mM oxidized L-Glutathione for crystallization to occur in conditions
identical to those described for the native Naa10pNaa15p complex. The crystals were
cryoprotected in the stepwise manner described above. To derivatize native crystals with
Pt (II), the crystals were transferred into mother liquor supplemented with 1mM K 2PtBr4
for 20 minutes before cryoprotection using the method described for the native
Naa10pNaa15p complex.
Datasets were collected at beamlines X25 and X29A at the National Synchrotron
Light Source (Brookhaven National Laboratory) and processed using HKL2000. For
phasing, a total of 1,000 degrees (1°/frame) were collected on a single derivatized crystal
(500 frames at the peak wavelength, and 500 frames at the inflection wavelength) to
reach desirable completeness and redundancy in the P1 space group, and datasets were
processed to 3.50 Å resolution. The two wavelength MAD data was used by the Hybrid
Substructure Search in Phenix to identify a total of 8 heavy atom sites in the asymmetric
unit and initial phases were obtained using SOLVE (Adams et al., 2010; Terwilliger and
Berendzen, 1999). Density modification was performed in Resolve by applying 4-fold
NCS (corresponding to each heterodimer) and using histogram matching and solvent
flattening (Terwilliger, 2000). Initially, the Naa15p helices were built as polyalanine
chains and the Naa10p molecules were manually placed into the density-modified map
using the program Coot. The resulting structure was used as a molecular replacement
model for the selenomethionine derivative dataset that was collected at the selenium peak
wavelength and processed to 3.35 Å resolution. A total of 80 selenium sites were located
manually in the asymmetric unit by contouring the map to 3.0σ and placing selenium
atoms in the peaks in Coot. These sites were used to place methionine residues in
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Naa15p, and manual model building was completed in coot using the methionine residues
as a guide. The final structure was used as a molecular replacement model for the highresolution datasets (500° of data each) of the Naa10pNaa15pAcCoA (3.10 Å
resolution) and the Naa10pNaa15pbisubstrate inhibitor (2.60 Å resolution) complexes.
Refinement of the binary complex structures was carried out in Phenix and 4-fold NCS
restraints were applied to two separate groups, the full-length Naa10p molecules, and
residues 100-731 of Naa15p. The positioning of the first 5 N-terminal helices in the
Naa15p subunit is slightly different in each heterodimer, so NCS could not be applied to
this region. TLS was also used in later stages of refinement (TLS groups defined using
the open access server). The backbone for the α20-α21 loop from residues 356-377 can
be traced, however it is largely disordered (average B-factor=196 Å2) as it likely samples
numerous conformations in the crystal.

No density was observed for a loop from

residues 633-641 and so this region was omitted from the final structure.

Naa15p

molecules were built starting between residues 1 and 5 depending on the chain and
dataset. The final models were checked for errors using a simulated annealing composite
omit map generated by AutoBuild in the Phenix suite of programs.
All surface area and distance calculations, as well as three-dimensional alignment
RMSDs and graphics were generated in PyMol (Delano Scientific LLC).

3.4.5 Acetyltransferase Assays
Naa10p•Naa15p acetyltransferase assays were carried out with 100 nM complex
at 25°C for 3-120 min. (3 min for wild type protein and longer for mutant complexes that
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were catalytically deficient) in 100mM Tris (pH 8.0) and 50 mM NaCl unless stated
otherwise. A saturating amount of AcCoA (500 μM) was used in all enzymatic reactions,
and the substrate peptide (NH2-SASEAGVRWGRPVGRRRRP-COOH; GenScript)
concentration was varied to determine steady-state catalytic parameters. The first seven
residues of this peptide correspond to the amino-terminal sequence of a protein that has
been shown to be highly amino-terminally acetylated in yeast while the C-terminal 12
residues form a basic tag that make the substrate compatible with our assay(Arnesen et
al.,

2009).

The

Glu-

amino-terminal

substrate

peptide

(NH2-

EEEIAALRWGRPVGRRRRP-COOH; Genscript) was designed with the same rationale,
except that the first seven residues are from the Naa10p in vivo substrate, γ-actin. The
Met- amino-terminal substrate peptide (NH2- MLGPEGGRWGRPVGRRRRP-COOH;
Genscript) also follows the design rationale described above, with the first seven residues
corresponding to the in vivo substrate, hnRNP F. In the assay, radiolabeled [14C]acetylCoA (4 mCi/mmol; PerkinElmer Life Sciences) was mixed with the substrate peptide and
allowed to incubate with enzyme in a 25 μL reaction volume at 25°C. To quench the
reaction, 20 μL of the reaction mixture was added to P81 paper discs (Whatman), and the
paper discs were immediately placed in wash buffer. Washes were then carried out three
times in 10 mM HEPES (pH 7.5), with each wash lasting 5 min, to remove unreacted
AcCoA. The papers were then dried with acetone and added to 4 ml of scintillation fluid,
and the signal was measured using a Packard Tri-Carb 1500 liquid scintillation analyzer.
Background control reactions were performed in the absence of enzyme. Reactions were
also performed in the absence of the substrate peptide to ensure that any possible signal
due to autoacetylation was negligible.
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For the uncomplexed Naa10p subunit, reactions with the Ser- amino-terminal
peptide were carried out for 1 hour using 500 μM AcCoA, substrate peptide (100-1,500
μM) and up to 1 μM untagged enzyme. No activity could be detected. Reactions with
the Glu- amino-terminal peptide were performed at 25°C for 30 minutes in the presence
of 200 nM enzyme and 500 μM AcCoA at various peptide concentrations (50-1000 μM).
For the NatA complex, substrate peptide Km and Vmax parameters were derived by
titrating the substrate peptide at eight different concentrations ranging from 100 to 1500
μm in the presence of 500 μM AcCoA.

To obtain kinetic data for the point mutants

L22A, Y26A, and Y139A, 500 nM of enzyme was used in the reaction. Additionally, the
AcCoA Km values for the wild type protein as well as the L22A mutant were determined
by titrating the AcCoA at 8 different concentrations (ranging from 20-300 μM) in the
presence of 1.5 mM substrate peptide. All reactions were performed in triplicate. All
radioactive count values were converted to molar units using a standard curve created
with known concentrations of radioactive acetyl-CoA added to scintillation fluid. The
program GraphPad Prism version 5.01 was used for all data fitting to the MichaelisMenten equation (Fersht, 1998).
Inhibition assays were carried out in a similar manner as described above. These
reactions were performed using 100nM wild type protein for 3 minutes in the buffer
described for the previous assays. IC50 values for Naa10p were calculated by titrating
inhibitor (CoA-SASEA: 0.01-120 μM and acetonyl CoA: 5-10,000 μM) into reaction
mixtures containing fixed concentrations of substrate peptide (500μM) and AcCoA (200
μM).

Similarly, IC50 values for NAA50 (expressed and purified as previously

described(Liszczak et al., 2011)) were calculated by titrating inhibitor (CoA-SASEA:
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0.01-240 μM and acetonyl CoA: 5-10,000 μM) into reaction mixtures containing fixed
concentrations of substrate peptide (1200 μM) and AcCoA (200 μM). To clarify, peptide
concentrations were held constant at Km.

To calculate the Ki of the CoA-SASEA

inhibitor versus AcCoA, substrate peptide concentration was held constant at 1200 μM
and kinetic curves were generated using AcCoA concentrations ranging from 15-500 μM
in the presence of inhibitor concentrations ranging from 0-15 μM. To calculate the Ki of
the CoA-SASEA inhibitor versus substrate peptide, AcCoA concentration was held
constant at 500 μM and kinetic curves were generated using peptide concentrations
ranging from 200-1000 μM in the presence of inhibitor concentrations ranging from 0-30
μM. All reactions described here were performed in duplicate and data were fit to a
sigmoidal dose-response curve using GraphPad Prism version 5.01.

3.4.6 Bisubstrate inhibitor synthesis
The peptide SASEA was synthesized on a 100 μmol scale using standard Fmoc
solid-phase synthesis techniques. Rink amide resin (100-200 mesh), Fmoc-Ala-OH,
Fmoc-Glu(tBu)-OH,

Fmoc-Ser(tBu)-OH,

and

2-(1H-benzotriazol-1-yl)-1,1,3,3-

tetramethyluronium hexafluorophosphate (HBTU) were purchased from Novabiochem
(currently EMD Millipore; Billerica, MA). All other reagents, including Sigmacote ®,
were purchased from Sigma-Aldrich (St. Louis, MO). A clean, oven-dried glass reaction
vessel (RV) was treated with Sigmacote and rinsed with dimethylformamide (DMF) prior
to use. Rink amide resin (151 mg; substitution 0.66 mmol/g) was transferred to the RV
and stirred with 6 mL DMF twice for 15 min. After each incubation, DMF was removed
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with vacuum suction. The beads were incubated with 20 % piperidine in DMF (5 mL)
for 20 min with magnetic stirring to remove the Fmoc protecting group from the resin.
The spent solution was removed with vacuum suction and the beads were rinsed
thoroughly with DMF. Excess DMF was removed with vacuum suction and the beads
were stirred with a solution of Fmoc-Ala-OH and HBTU in DMF (5 equiv; 83 mM, 6
mL) and diisopropylethylamine (10 equiv; 175 μL). After 30 min, the spent solution was
drained from the RV and the beads were washed extensively with DMF. Excess DMF
was removed with vacuum suction. Subsequent amino acids were added iteratively using
analogous Fmoc-deprotection and coupling procedures. After removal of the final Nterminal Fmoc-protecting group, bromoacetic acid was coupled to the peptide as an
active O-acylisourea using carbodiimide chemistry. Bromoacetic acid (10 equiv; 139
mg, 1 mmol) was pre-activated with N,N'-diisopropylcarbodiimide (20 equiv; 309 μL, 2
mmol) in 2 mL dry CH2Cl2 for 20 min with stirring. The solvent was then removed
under reduced pressure and the residue was transferred to the RV as a solution in 6 mL
DMF. The resulting slurry was allowed to react for 1 h with constant stirring. The resin
beads were then thoroughly washed with DMF and CH2Cl2.

Residual solvent was

removed with vacuum suction and the beads were dried under vacuum for 30 min. A
cocktail of trifluoroacetic acid (TFA)/triisopropylsilane/water (38:1:1 v/v) was used for
global deprotection and resin cleavage. The resin beads were incubated with fresh 6 mL
portions of this solution for 60 min and then 30 min on a rotisserie. The cleavage solution
was drained from the RV under N2 flow after each incubation. The solutions were
combined and concentrated under reduced pressure. The residue was dissolved in a
H2O/CH3CN solution (3:1 v/v) and lyophilized. The crude, lyophilized powder was
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dissolved in 3 mL triethylammonium bicarbonate buffer, pH 8.00. A 1 mL portion of this
solution was mixed with coenzyme A hydrate (25 mg, 33 μmol) and the resulting
solution was allowed to react for 4 h at room temperature and then overnight at 4 °C.
The peptide conjugate was purified by reversed-phase high-performance liquid
chromatography (HPLC) using a Varian ProStar HPLC instrument outfitted with a diode
array detector (currently Agilent Technologies; Santa Clara, CA) and Vydac 218TP C18
analytical and prep columns (Grace/Vydac; Deerfield, IL) with a linear solvent gradient.
The aqueous phase was 0.1 % TFA in H2O and the organic phase was 0.1 % TFA in
CH3CN. The gradient remained isocratic at 98 % aqueous phase for 5 min, before
ramping to 81 % aqueous phase over 16 min, then to 0% aqueous phase over 6 min, then
returning to 98% aqueous phase during a 9 min wash out period. The peptide conjugate
eluted around 15 min with this method. An analytical trace of the purified compound is
shown in Figure 3.13.

Purified material was lyophilized.

Matrix-assisted laser

desorption ionization (MALDI) mass spectra were collected with a Bruker Microflex
LRF MALDI-TOF mass spectrometer to confirm identity. MALDI-MS(-) m/z clacd for
C40H65N13O26P3S- [M-H]- 1268.31, found 1268.32.

3.4.7 Materials and methods (‘Future directions’)
Isolation of ribosomes was carried out as previously described (Ben-Shem et al.,
2011; Ben-Shem et al., 2010).

Purified ribosomes were resuspended in a buffer

containing 10 mM HEPES (pH 7.5), 50 mM KOAc, 10 mM NH4Cl, 5 mM Mg(OAc)2, 5
mM BME and NatA was dialyzed into an identical buffer and immobilized on the nickel
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column. Ribosomes were passed over the column 5 times and the resin was subsequently
washed with 10 CV of lysis buffer supplemented with 25 mM imidazole.

The

NatAribosome complex was eluted from the column using lysis buffer supplemented
with 300 mM imidazole. The elution was sent directly to collaborators for EM studies.
Control experiments were performed to show that ribosome does not interact with nickel
resin in the absence of the NatA complex.
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Figure 3.13 Analytical HPLC trace of purified SASEA-CoA. Absorbance at 260nm
has been normalized. The solvent gradient has been provided in the supplemental text.
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3.5 Future directions and NatAribosome complex studies
There are many outstanding questions in the NAT field regarding the
NatAribosome interaction. In vivo NatAribosome pull-downs provide evidence that
ribosomal proteins Rpl25p and Rpl35p in Saccharomyces cerevisiae, which are in close
proximity to the ribosomal exit tunnel, are responsible for the NatA interaction (Polevoda
et al., 2008).

However, it is unclear whether all NAT complexes alternate with one

another for this binding site during this translation or if the NATs are able to associate
with the ribosome simultaneously. It is also possible that different ribosomes selectively
interact with different NAT complexes and that there is no competition between NATs
for interaction with the ribosome. This scenario would require a mechanism of ribosomal
mRNA selectivity to ensure that each translated protein meets the substrate requirements
for the corresponding NAT.
To explore these possibilities, we isolated ribosomes from Schizosaccaromyces
pombe and formed a ribosomeNatA complex for electron microscopy (EM) studies. We
used nickel affinity pull-downs to verify that His-NatA is able to interact with the
ribosome in vitro and found that while the interaction does occur, we are unable to isolate
a 1:1 complex and frequently had to work with a solution containing a large molar excess
of NatA (Figure 3.14A and B).

There are several factors that may be affecting the

stoichiometry of our complex. It is very unlikely that the NatA complex binds to the
ribosome with high affinity. There are a plethora of proteins that interact with the
ribosome near the peptide exit tunnel throughout translation, and it is a distinct possibility
that they have overlapping binding sites and are only transiently associated. Furthermore,
activity of most of these proteins, such as methionine aminopeptidases and NATs, is only
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observed at certain points during translation (see Chapter 1) and it would not be prudent
for the ribosome to develop a high affinity for these enzymes. A non-specific interaction
region with a low affinity for binding partners would support the dynamic equilibrium of
ribosomal binding partners that is observed near the peptide exit tunnel during
translation. It is also possible that the unbound ribosomes from our pull-down are
dedicated to interacting with other NATs, or that the NatA binding site is occupied by
endogenous proteins. To circumvent these issues, our EM collaborators are attempting to
pick individual, NatA-bound ribosomes.

Optimization of the purification is also

underway to try to separate excess NatA from the ribosomeNatA complex.
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Figure 3.14 NatA interacts with the 80S ribosome in vitro. (A) His-tagged NatA
mixed with the untagged ribosome and purified using nickel resin. (B) The pull-down
experiment shown in (A) in the absence of NatA.
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CHAPTER 4

Implications for the evolution of eukaryotic amino-terminal acetyltransferase (NAT)
enzymes from the structure of an archaeal orthologue

Liszczak et al., 2013 (submitted)
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4.1 Introduction and summary
As we have seen in previous chapters, NatA and Naa50p use different catalytic
strategies to achieve substrate-specific acetylation. In the NatA complex, binding of
noncognate substrate sequences is possible; however, the enzyme-substrate interaction
would inactivate the enzyme by displacing an essential general base that is located in the
substrate amino-terminal residue side chain-binding pocket (P1 pocket). On the other
hand, Naa50p excludes binding of NatA substrate peptides through the use of an open,
hydrophobic P1 pocket that specifically selects for an amino-terminal Met- residue. As a
result, residues involved in deprotonation of the Met- substrate peptide are located across
the active site from this pocket, where NatA has no catalytically essential residues. In
addition to characterizing detailed strategies for catalysis, these structures also reveal a
conserved three-dimensional NAT fold that appears to be required for activity and
describe how the Naa15p auxiliary subunit is able to stabilize Naa10p in this active
conformation.
While only six amino-terminally acetylated proteins have been identified in E.
coli, large-scale proteomics studies of three different archaeal species revealed that ~1429% of all proteins isolated were acetylated at their amino-terminus, suggesting that
prevalence of amino-terminal acetylation in this domain is somewhere between
prokaryotes and eukaryotes (Aivaliotis et al., 2007; Falb et al., 2006; Kirkland et al.,
2008; Polevoda and Sherman, 2003b; Soppa, 2010; Waller, 1963). Analysis of the
thermophilic archaea Sulfolobus solfataricus genome allowed for identification of a
protein with 37% sequence identity to human Naa10p, which is believed to be the only
NAT in this species (Mackay et al., 2007). In agreement with this hypothesis, the same
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study showed that this protein is able to independently acetylate NatA substrates as well
as amino-terminal Met- substrates in vitro (Mackay et al., 2007). Furthermore, no
auxiliary subunit homologues can be identified in this genome, suggesting that this
archaeal species dedicates just one protein to a task that requires at least nine unique
proteins in humans. This ancestral NAT variant, herein referred to as ssNAT, is an ideal
candidate for probing the evolution of this family of enzymes and the strategies they
employ to achieve substrate-specific acetylation.
In order to gain insight into the evolution of NAT enzymes, we solved the x-ray
crystal structure of an archaeal NAT from Sulfolobus solfataricus to 1.98 Å resolution.
Through the use of mutagenesis and kinetic analysis, we show that the active site of this
enzyme represents a hybrid of the NatA and NatE active sites and we highlight features
of this protein that allow it to facilitate catalysis through both the NatA and NatE
catalytic strategies. Notably, this is the first acetyltransferases to be identified that has
the ability to facilitate substrate acetylation through two independent catalytic strategies.
Taken together, the structural and biochemical data presented here has implications for
the evolution of eukaryotic NAT enzymes and the substrate specificities therein.

4.2 Results
4.2.1 Overall structure of the active ssNAT enzyme
Crystals of the ssNAT enzyme (residues 50-216 of 215) bound to AcCoA were
obtained using recombinant protein expressed in E. coli and diffracted to 1.98 Å
resolution in the spacegroup C2 with 1 molecule per asymmetric unit cell. The structure
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was determined with molecular replacement using ssARD1 (PDB ID: 2X7B) as a search
model. Electron density was observed from residues 60-216 and the structure was
refined to a final Rwork/Rfree of 19.9%/24.3% (Table 4.1). The ssNAT structure adopts a
Gcn5-related N-acetyltransferase (GNAT) fold with a central AcCoA binding core region
and flanking N- and C- terminal segments most similar to the active form of the human
NatA catalytic subunit Naa10p (RMSD = 1.46 Å) and NatE/Naa50p (RMSD = 1.98 Å)
(Figures 4.1A and 4.1B). ssNAT also contains an extended β3-β4 loop that is the only
nonconserved feature in the catalytic core of this enzyme relative to the eukaryotic NATs
(Figure 4.1B). Furthermore, an alignment of ssNAT with the uncomplexed, inactive form
of Naa10p reveals more significant differences, particularly in regard to the position of
the α1-loop-α2 segment (Figure 4.1C). More specifically, the C-terminal portion of the
α1 helix in ssNAT is extended by one complete helical turn, a conformation that Naa10p
can only adopt in the presence of its auxiliary subunit. This helix extension, which is also
present in Naa50p, seems to be crucial for proper positioning of the α1-α2 loop, a region
that has been shown to be essential for substrate-specific acetylation by both eukaryotic
NATs discussed here. Notably, the α1-loop-α2 segments in ssNAT, Naa50p and the
active form of Naa10p all adopt nearly identical conformations, which is in support of a
previous report that ssNAT is independently active.
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Table 4.1 Data collection and refinement statistics for ssNAT.

Values in parentheses are for the highest resolution
shell. Rfree was calculated using 5% of the
reflection data chosen randomly and omitted at the
start of refinement.
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Figure 4.1 Overall structure of the ssNAT enzyme. (A) The structure of the ssNAT
enzyme (tan cartoon representation) bound to AcCoA (gray stick representation).
Elements of secondary structure have been labeled. (B) A three-dimensional alignment
of the ssNATAcCoA complex with NAA50p (red cartoon representation) and the
complexed, active form of Naa10p (teal cartoon representation). A color-coded legend is
also included. (C) A three-dimensional alignment of the ssNATAcCoA complex with
the uncomplexed, inactive Naa10p (silver cartoon representation). Regions of negligible
structural variation are shown at 50% transparency. The first two α-helices are labeled.
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4.2.2 Implications for the evolution of NAT substrate-acetylation specificity
The structure of the NatA complex bound to a bisubstrate peptide-CoA conjugate
inhibitor established the position of the substrate amino-terminal residue in the active site
of the catalytic subunit. An alignment of the active site from this structure with the
corresponding region of ssNAT reveals that all key catalytic and cognate substrate
binding residues in the active site of Naa10p are conserved in ssNAT (Figure 4.2A).
Specifically, residues L82, E84 and Y86 in the α1-α2 loop of ssNAT align with
corresponding residues of Naa10p.

Similarly, ssNAT residues R178 and Y203

correspond to Naa10p residues R113 and Y139. In contrast, another alignment of the
ssNAT active site with the ternary Naa50p•CoA•substrate peptide fragment structure
shows significant differences in the amino-terminal residue binding pockets of the two
enzymes (Figure 4.2B). In Naa50p, residues F27, P28, V29 and I142 align with ssNAT
residues L82, E84, Y86 and R178, and form a substantially more open, hydrophobic
pocket that is ideal for the amino-terminal Met- substrate for Naa50p. Indeed, it appears
that ssNAT-E84 would clash with the Met- side chain of a Naa50p substrate peptide
(Figure 4.2C). Therefore, at first glance, it appears that ssNAT is more tailored for
binding to NatA vs. NatE substrates.
In order to directly establish the ability of ssNAT to process NatA and E
substrates, we generated catalytic parameters for the enzyme against amino-terminal Serand Met- containing peptides (Tables 4.2 and 4.3).

Consistent with the structural

comparison, we observed that ssNAT had a preference for the NatA/Naa10p over the
NatE/Naa50p substrate; specifically, ssNAT had a Km for the Ser- amino-terminal
Naa10p substrate that is 7.4-fold lower than its Km for the Naa50p Met- amino-terminal
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substrate and the kcat towards the Ser- amino-terminal substrate is 4.5-fold higher than the
kcat towards the Met- amino-terminal substrate (Figure 4.3A and B). While this enzyme
displays more favorable catalytic parameters with the Ser- substrate, its ability to modify
amino-terminal Met- substrates is in stark contrast with NatA, which shows only
background acetylation levels with similar peptides. To directly test the importance of
ssNAT-E84 in N-terminal residue processing, we prepared ssNAT-E84A/V mutants and
assayed their ability to process a Met- amino-terminal substrate peptide. As expected, we
found that these mutants were more accommodating towards the Met substrates, as
evidenced by increases in the kcat of the enzyme by 4.6-fold and 2.5-fold, respectively,
towards the Met- amino-terminal substrate while the kcat towards the Ser-amino-terminal
substrate was unaffected. These mutants also resulted in an increased K m for the Seramino-terminal substrate (4.1-fold and 3.5-fold, respectively) with no effect on the Km for
the Met- amino-terminal substrate. Furthermore, an alanine point mutation at R178,
which also contributes to the hydrophilicity of the binding pocket and forms an ionic
interaction with E84, exhibited a 2.5-fold increase in kcat towards the Met- aminoterminal substrate with no effect on the kcat towards the Ser-amino-terminal substrate.
These results strongly support our previous hypothesis that Naa50p, which has a valine
(V29) in the position of ssNAT-E84, uses a more open hydrophobic binding pocket to
achieve Met- amino-terminal substrate binding specificity.
The Y86 and Y203 residues in ssNAT are conserved in both Naa10p and Naa50p,
and form hydrogen bonds with substrate peptide backbone carbonyl groups in each of the
previously reported structures (Figure 4.2A and B). While these residues do form van der
Waals interactions with the amino-terminal residue of the substrate peptide in each
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structure, it seems that their primary function is to anchor the substrate peptide to the
enzyme in a catalytically competent position and it is unlikely that they play a role in
substrate specificity. We found that the ssNAT-Y86F and ssNAT-Y203F mutants do not
affect the Km in the context of the Met- amino-terminal substrate but do show decreases
of 3.2-fold and 5.2-fold in kcat, respectively. The same mutations show no effect on
catalysis or substrate binding relative to wild type enzyme in the context of the Seramino-terminal substrate. Thus, the substrate peptide backbone interactions are more
critical for productive binding of the Met- amino-terminal substrate, likely because the
ssNAT amino-terminal residue binding pocket favors binding of the Ser- substrate over
the Met- substrate.
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Figure 4.2 ssNAT active site and catalytic strategies. (caption on following page)
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Figure 4.2 (continued) (A) A three-dimensional alignment of the ssNAT active site
(tan) with the corresponding region in Naa10p (teal). Putative ssNAT substrate binding
and catalytic residues are shown in stick format as are corresponding residues in Naa10p.
The bisubstrate inhibitor from Naa10p is shown in silver stick format and residues from
the peptide portion of this inhibitor are labeled with orange numbers. Key secondary
structure elements are also labeled. Hydrogen bonds are represented as black dotted
lines.

(B) A three-dimensional alignment of the ssNAT active site (tan) with the

corresponding region in Naa50p (pink). Putative ssNAT substrate binding and catalytic
residues are shown in stick format as are corresponding residues in Naa50p. The CoA
and substrate peptide ligands from Naa50p are shown in yellow stick format and residues
from the substrate peptide are labeled with yellow numbers. Key secondary structure
elements are also labeled. Hydrogen bonds are represented as black dotted lines. (C)
ssNAT catalytic residues from catalytic strategy 1 are shown in tan stick format and
aligned with catalytic residues from Naa50p (pink stick format). A conserved active site
water molecule is shown as a light blue sphere. The bisubstrate inhibitor from Naa10p is
shown in silver stick format and the CoA and substrate peptide ligands from Naa50p are
shown in yellow stick format. Residues from the peptide portions of these ligands are
labeled as orange numbers. (D) ssNAT catalytic residues from catalytic strategy 2 are
shown in tan stick format and Naa10p residues are shown in teal stick format. The
bisubstrate inhibitor from Naa10p is shown in silver stick format and the CoA and
substrate peptide ligands from Naa50p are shown in yellow stick format. Residues from
the peptide portions of these ligands are labeled as orange numbers. A hydrogen bond is
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represented as a black dotted line.

A color-coded legend for the panel has been included

for clarity.
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Figure 4.3 Catalytic parameters for mutant ssNAT enzymes relative to wild type.
(caption on following page)
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Figure 4.3 (continued) (A) kcat values for the wild type (WT) ssNAT and accompanying
mutants towards both the Ser- amino-terminal substrate peptide (silver bars) and the Met- aminoterminal substrate peptide (yellow bars). All values have been normalized to the kcat value
calculated for the WT enzyme. (B) Km values for the WT ssNAT and accompanying mutants
towards both the Ser- amino-terminal substrate peptide and the Met- amino-terminal substrate
peptide. All values have been normalized to the Km value caluculated for the WT enzyme. All
numbers were calculated by fitting data to the Michaelis-Menten equation. A complete table of
kinetic data can be found in SI Materials and Methods.
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Table 4.2 The kcat values calculated for all ssNAT variants with the Ser- substrate
peptide and the Met- substrate peptide.
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Table 4.3 The Km values calculated for all ssNAT variants with the Ser- substrate
peptide and the Met- substrate peptide.
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4.2.3 Characterization of two independent catalytic mechanisms strategies by ssNAT
Naa50p uses a two-base mechanism to carry out substrate α-amino group
deprotonation and facilitate catalysis. These two bases, Naa50p-Y73 and Naa50p-H112,
are on the β3 and β4 strands respectively, and are representative of the traditional general
base positions in GNAT enzymes (Figure 4.2B) (Marmorstein, 2004; Vetting et al.,
2005). In Naa10p, the Naa50p-Y73 and Naa50p-H112 residues are replaced by Naa10pH72 and Naa10p-H111, respectively, of which Naa10p-H72 is flipped out of the active
site and not in a position to act as a general base (Figure 4.2A). It is therefore not
surprising that neither of these residues is crucial for catalysis by Naa10p.

The

corresponding active site positions in ssNAT are occupied by ssNAT-H137 and ssNATE176, both of which have side chains directed into the active site that align well with
Naa50p-Y73 and Naa50p-H112. To assess the roles of ssNAT-H137 and ssNAT-E176 in
catalysis, we used site-directed mutagenesis to make single and double mutants at these
sites and kinetically characterized the mutant enzymes.

The ssNAT-H137A/F/Q

mutations were found to all inactivate the enzyme toward the Met- substrate while the
ssNAT-E176Q mutant showed a 5.2-fold reduction in kcat towards this substrate with a
negligible effect on Km. Although it is possible that ssNAT-H137 is also involved in
productive substrate binding, the ssNAT enzyme seems to use an Naa50p-like two
general base strategy (herein referred to as ‘strategy 1’) to deprotonate the α-amino group
of the Met- amino-terminal substrate (Figure 4.2C). Remarkably, however, we found that
the three mutations discussed here all have less than a 2-fold effect on the kcat of the
enzyme towards the Ser- amino-terminal substrate, and the ssNAT-H137A/E176Q is the
only mutant that has an effect on Km, which increases by 4.3-fold. This finding suggests
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that there is an alternate catalytic strategy within the enzyme that is able to facilitate the
acetylation reaction in the presence of the Ser- amino-terminal substrate.
Structural and mutational analysis of Naa10p in the context of the NatA complex
suggests that Naa10p-E24 is an essential general base residue as evidenced by a >100fold reduction in catalysis observed for the E24Q mutant, with no effect on Km.
Additionally, this study revealed that Naa10p-R113 and Naa10p-Y139 are also in
position to participate in the catalytic mechanism and point mutations at these sites
decrease the rate of catalysis relative to the wild type enzyme. Interestingly, all of these
residues are conserved in the ssNAT enzyme, where ssNAT residues E84, R178 and
Y203 correspond to Naa10p residues E24, R113 and Y139. We found that the sssNATE84Q mutant is only 1.8-fold less active towards the Ser- substrate relative to the wild
type enzyme. This result suggests that ssNAT-E84 (at least on its own) does not play an
analogous general base role as Naa10p-E24 for the Ser- amino terminal substrate. We
then addressed the possibility that ssNAT-E84 might cooperate with ssNAT-E176 or
ssNAT-H137 for Ser- substrate acetylation. Analysis of the ssNAT-E84Q/E176Q and
ssNAT-E84Q/H137A double mutants revealed that the ssNAT-E84Q/E176Q mutant had
no detectable activity towards the Ser- amino terminal substrate while the ssNATE84Q/H137A mutant had only a minor effect on catalysis (1.5-fold decrease in kcat) but
showed a 7.4-fold increase in Km. We also assessed the effect combining the ssNATE176Q mutant with mutants of either ssNAT-R178 or ssNAT-Y203 and found that the
ssNAT-E176Q/R178A and ssNAT-E176Q/Y203F mutants had a 2-fold or less decrease
in kcat towards the Ser- amino-terminal substrate. Taking these results together reveals
that residues ssNAT-E84 and ssNAT-E176 cooperate as general base residues for ssNAT
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acetylation through an alternative catalytic strategy (strategy 2) for acetylation of the Sersubstrate (Figure 4.2D). The observation that the ssNAT-E84Q/E176Q mutant is also
unable to acetylate the Met substrate likely reflects the importance of ssNAT-E176 for
Met-substrate acetylation in the context of an amino-terminal binding pocket with an
altered electrostatic environment, which potentially effects the position of the α-amino
group within the active site.

4.2.4 Non-conserved loop region potentiates ssNAT activity
Despite a nearly identical active site landscape between ssNAT and Naa10p,
Naa10p is not able to facilitate catalysis via catalytic strategy 1.

The active site

alignment shows that ssNAT-Y174 is one of the only residues in the active site that is not
conserved in Naa10p (Figure 4.2A). Additionally, this residue appears to play a role in
positioning ssNAT-H137 for Met- amino-terminal substrate catalysis by forcing this
general base residue into the active site. The residue corresponding to ssNAT-Y174 in
Naa10p, Naa10p-S109, lacks the bulky side chain required to force the corresponding
base residue, Naa10p-H72, into the active site of the enzyme. Consequently, the Naa10pH72 side chain is able to flip out of the active site into a catalytically incompetent
position. Contrary to this hypothesis, the ssNAT-Y174S point mutant, which mimics the
Naa10p active site, has no effect on catalysis and implies that ssNAT-H137 is held in
position by other residues in the local environment. Indeed, inspection of the alignment
of ssNAT with the Naa10p and Naa50p structures (Figure 4.1B) reveals that the loop
segment connecting the β3 and β4 strands of the ssNAT core region is significantly more
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extended than the corresponding loops of Naa10p and Naa50p and points towards the
ssNAT active site (Figure 4.4A). In particular, residues ssNAT-N125 and ssNAT-I126, at
the tip of the β3-β4 loop, appear to make intramolecular interactions with the B5 and B7
strands. To determine if the β3-β4 loop region participates in catalysis in some way, we
prepared the ssNAT-N125A/I126A mutant, which we found is unable to acetylate the
Met- amino-terminal substrate and exhibits a 4.0-fold reduction in kcat towards the Seramino terminal substrate as well as a 3.9-fold increase in Km relative to the wild type
enzyme. Based on this observation, we conclude that the extended β3-β4 loop region of
ssNAT likely has a stabilizing effect on the three dimensional fold of the active site and is
able to prime the enzyme for catalysis of the Met- substrate, and to a lesser extent the
Ser- amino terminal substrate.
Interestingly, there are several GNAT enzymes that capitalize on the variability of
the β3-β4 loop region for functional gain (Figure 4.4B). In glucosamine-6-phosphate
acetyltransferase (GNA1; PDB ID: 1I1D) and the histone acetyltransferase HPA2 (PDB
ID:

1QSM), this loop mediates biologically relevant dimerization and facilitates

substrate binding by contributing to active site architecture of the dimer partner (Figure
4.4 C and D), while in serotonin N-acetyltransferase (AANAT; PDB ID: 1L0C) this
region is responsible for orienting the arylalkylamine substrate in the active site through
an intramolecular mechanism (Figure 4.4E) (Angus-Hill et al., 1999; Peneff et al., 2001;
Scheibner et al., 2002).
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Figure 4.4 The β3-β4 loop region in ssNAT and other GNAT enzymes. (caption on
following page)
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Figure 4.4 (continued) (A) A zoom view of the β3-loop-β4 region of ssNAT. Key
residues (shown in tan stick format) and secondary structure elements are labeled.
AcCoA is represented in gray stick format. (B) An alignment of GNA1 (light blue
cartoon representation), HPA2 (a neon green cartoon representation), AANAT (pink
cartoon representation
representation, respectively) showing conserved secondary structure elements at 50%
transparency.
transparency.

The β3-loop-β4 motifs from these enzymes are shown with no
The variable region has been encircled and labeled.

Key secondary

structure elements are also labeled. (C) GNA1 (light blue cartoon, 50% transparancy)
bound to CoA (gray stick representation) and the GlcNAc6P substrate (silver stick
representation) with key secondary structure elements labeled and the β3-loop-β4 motif
shown with no transparency. Secondary structure elements from the β3-loop-β4 motif of
the second molecule in the dimer (dark blue cartoon representation) are also labeled with
a (') symbol. (D) HPA2 (neon green cartoon, 50% transparency) bound to AcCoA (gray
stick representation) with key secondary structure elements labeled and the β3-loop-β4
motif shown with no transparency. Secondary structure elements from the β3-loop-β4
motif of the second molecule in the dimer (dark green cartoon representation) are also
labeled with a (') symbol. (E) AANAT (light red cartoon, 50% transparency) bound to a
bisubstrate analogue CoA-S-Acetyltryptamine (silver stick representation) with key
secondary structure elements labeled and the β3-loop-β4 motif shown with no
transparency. The β3-β4 loop is colored in dark red.
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4.2.5 The length of the α1 helix has implications for obligate heterodimerization of
certain NAT enzymes
The C-terminal portion of the α1 helix is the only region of ssNAT that is
sequentially more similar to Naa50p than to Naa10p (Figure 4.5A). Interestingly, as
shown in Figures 4.1B and 4.1C, the length of this helix is critical for the placement of
the α1-α2 loop, which harbors several residues that facilitate substrate binding and/or
catalysis in all three NATs discussed here. The independently active ssNAT and Naa50p
enzymes have similar α-helix-stabilizing residues in the C-terminal portion of the α1
helix (Figure 4.5A and B), which is able to undergo an additional helical twist relative to
monomeric Naa10p (Figure 4.1C). As a result, the α1-α2 loop in both ssNAT and Naa50p
is able to adopt a conformation that is suitable for catalysis in the absence of an auxiliary
subunit. In Naa10p, these helix-stabilizing residues are not conserved; consequently, the
length of the α1 helix and position of the α1-α2 loop cannot support catalysis by the
enzyme in the absence of auxiliary subunit binding. It is therefore tempting to speculate
that the length of this helix may dictate whether or not a NAT enzyme needs a binding
partner for catalytic activation.
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Figure 4.5

Conservation between the ssNAT α1-loop-α2 motif and the

corresponding regions of Naa10p and Naa50p. (caption on following page)
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Figure 4.5 (continued) (A) A surface conservation map for ssNAT with Naa10p and
Naa50p centered on the α1 helix. Regions in which aligned residues are identical are
shown in dark red, regions in which aligned residues are highly similar are shown in light
red, and regions in which aligned residues are not similar are shown in light blue. Key
secondary structure elements are labeled. (C) A sequence alignment of the α1-loop-α2
motif in ssNAT with the corresponding regions of Naa10p and Naa50p. Secondary
structure elements observed in the 3-dimensional structure are shown just above the
sequence. Residue numbers correspond to ssNAT. Catalytic and substrate binding
residues from ssNAT are denoted with a (•) and (✚), respectively, above the residue in
the sequence.
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4.3 Discussion
Because Sulfolobus solfataricus only contains one NAT protein to acetylate
substrates with different N-terminal residues, it appears this enzyme has a
“compromised” strategy to acetylate many varied substrates. In particular, we found the
ssNAT contains an active site that is a hybrid of the NatA and NatE active sites, and as a
result can facilitate acetylation of Met- and non-Met-containing amino-terminal substrate
peptides. We show that while ssNAT has higher sequence similarity to Naa10p over
Naa50p (34% vs. 24% sequence identity, respectively) and correspondingly has a
preference for Ser- over Met-amino-terminal substrates, it still is able to accommodate a
Met- amino-terminal substrate. Our results indicate that for the Met- amino-terminal
substrate, ssNAT uses H137 in particular, but also E176 as general base residues for
catalysis, while it uses E84 and E176 as general base residues for the Ser-amino-terminal
substrate. We also show that ssNAT utilizes a structural feature that is not conserved in
the eukaryotic NATs, the β3-β4 loop, to stabilize the position of key residues involved in
substrate acetylation, and Met- amino-terminal substrate acetylation in particular.
The presence of two different catalytic strategies that facilitate the reaction of a
single enzyme towards different substrates is very rare and, to our knowledge, this is the
first acetyltransferase to be identified that can carry out the deprotonation event through
different pathways. One explanation for the existence of the two catalytic strategies is
that ssNAT represents a ‘snapshot’ in the evolution of the eukaryotic NATs, which
subsequently evolved into separate enzymes with increased specificity towards different
substrates. Consequently, we propose that evolutionary events, such as mutations to the
active site, and the β3-β4 loop region and the C-terminal portion of the α1 helix, led to a
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diverse family of monomeric and heterodimeric eukaryotic NATs with different substrate
specificities and catalytic mechanisms.

4.4 Materials and methods
4.4.1 ssNAT expression and purification
The ssNAT gene (encoding residues 50-216) was cloned out of Sulfolobus
solfataricus genomic DNA (ATCC) and engineered into a modified pETDUET vector
containing a TEV protease cleavable 6X-His tag. The resulting plasmid was transformed
into Rosetta (DE3)pLysS competent E. coli cells, grown to an OD600=0.7 and induced
with 0.5 mM IPTG at 16°C for ~16 hours. Cells were isolated by centrifugation and
lysed by sonication in a buffer containing 25 mM Tris (pH 8.0), 1 M NaCl, 10 mM β-ME
and 0.5mM PMSF (Sigma-Aldrich). The solution was isolated and passed over Ni-resin
(Thermo Scientific), which was subsequently washed with > 20 column volumes of lysis
buffer supplemented with 25 mM imidazole (Fisher Scientific). The protein was eluted
in the same buffer with an imidazole gradient (25-500 mM imidazole) and TEV protease
was added to fractions containing the target protein for the duration of a 14-hour dialysis
into lysis buffer adjusted to 300 mM NaCl.

The solution was passed through an

additional nickel column to remove TEV protease as well as any uncut ssNAT. The resin
was then washed with ~ 7 column volumes of dialysis buffer supplemented with 25 mM
imidazole, which was pooled with the initial flow through. This solution was dialyzed
into a buffer containing 25mM Tris (pH 8.5), 50 mM NaCl and 5 mM β-ME and loaded
onto a 5 mL HiTrap Q ion exchange column (GE Healthcare). Although the protein did
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not stick to this column, a major impurity did interact with the column and so this step
was still essential for obtaining high purity protein. Peak fractions were concentrated to
~1-2 mL (10kDa concentrator; Amicon Ultra, Millipore) and loaded onto an s75prep gel
filtration column (GE Healthcare) that was pre-equilibrated in a buffer containing 20 mM
Tris (pH 7.5), 150 mM NaCl and 10% glycerol. The second of two peaks from the sizing
column corresponded to monomeric ssNAT and so this peak was pooled and
concentrated to 10 mg/mL as measured by UV280 absorbance (extinction coefficient =
25,000), for crystallization trials.

All ssNAT mutants were generated using the

Stratagene QuickChange protocol and protein harboring point mutations was expressed
and purified using the protocol described above (Braman et al., 1996). All mutants
exhibit gel filtration profiles similar to that of the wild type enzyme, suggesting that they
are properly folded.

4.4.2 ssNAT crystallization and structure determination.
Prior to crystallization, ssNAT was mixed with AcCoA (Sigma-Aldrich) at a 1:3
molar ratio. Initial crystallization hits were obtained at 20°C using hanging drop vapor
diffusion with two different well conditions; the first containing 20% PEG 3350
(Hampton Research) and 0.2 M zinc acetate (Hampton Research) and the second
containing 20% PEG 3350 and 0.02 M zinc chloride (Hampton Research). The zinc
acetate condition showed better initial diffraction and optimization of this condition
resulted in a well containing 14% PEG 3350 and 0.1 M zinc acetate. The best diffracting
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crystals were from a drop set up using a protein concentration of 7.5 mg/mL and took 3-7
days to reach maximum dimensions.
Diffraction data were collected on a Rigaku MicroMax-007 HF rotating anode xray generator with a Saturn 944+ CCD detector and processed to 1.98 Å resolution using
HKL2000 (Otwinowski and Minor, 1997). A total of 150 degrees (1°/frame) were
collected and indexed in the C2 space group. Molecular replacement was performed
using the program Phaser and the apo structure of ssARD1 (PDB ID: 2X7B) as a search
model (McCoy et al., 2007). This solution yielded high electron density maps and initial
rounds of manual model building and refinement were performed using Coot (Emsley
and Cowtan, 2004).

Subsequent rounds of refinement were performed using

Phenix.Refine to refine XYZ coordinates and individual atomic displacement parameters
(Adams et al., 2010). Iterative rounds of phenix refine and manual refinement in coot
were used to reach final Rwork and Rfree values of 19.9% and 24.3%, respectively. The
final map was checked for errors using a composite omit map generated by AutoBuild in
the Phenix suite of programs (Adams et al., 2010).
All three-dimensional alignment RMSDs as well as graphics were generated in
PyMol (Delano Scientific LLC).

4.4.3 Acetyltransferase assays
All assays were performed in the presence of 500 nM ssNAT enzyme at 37°C in a
buffer containing 25 mM Tris (pH 8.0) and 50 mM NaCl. It is likely that the in vivo kcat
values for this enzyme are much higher than we report here because the enzyme is from a
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thermophilic archaeal species that thrives in environments that reach temperatures much
greater than 37°C. For Ser- peptide assays, reaction times were generally 30 minutes,
however, catalytically deficient mutants were tested for up to 2 hours. For Met- peptides
assays, reaction times were generally 120 minutes, however, times ranged from 30
minutes to 6 hours depending on the effect of the mutant. Mutants that did not show
activity levels at least 2-fold greater than background readings were considered inactive.
A saturating amount (500 μM) of radiolabeled [14C]acetyl-CoA (4 mCi/mmol;
PerkinElmer Life Sciences) was used in all enzymatic reactions and the substrate peptide
concentration was varied to determine steady-state catalytic parameters.
concentration

of

the

Ser-

peptide

The

(NH2-SASEAGVRWGRPVGRRRRP-COOH;

GenScript) ranged from 25-1000 μM. The first seven residues of this peptide correspond
to the amino-terminal sequence of a threonyl-tRNA synthetase protein that has been
shown to be 100% amino-terminally acetylated in yeast and the C-terminal 12 residues
form a basic tag that is required for compatibility with our filter paper binding assay. The
concentration of the Met- peptide (NH2-MLGPEGGRWGRPVGRRRRP-COOH;
GenScript) ranged from 50-1200 μM. The first seven residues of this peptide correspond
to the amino-terminal sequence of hnRNP F, which is the only known biologically
relevant substrate for the Naa50p enzyme and the C-terminal 12 residues are identical to
that of the Ser- peptide. In the assay, radiolabeled [14C]AcCoA was mixed with the
substrate peptide and allowed to incubate with enzyme in a 25 μL reaction volume. To
quench the reaction, 20 μL of the reaction mixture was added to P81 paper discs
(Whatman), and the paper discs were immediately placed in wash buffer (10 mM HEPES
(pH 7.5). Papers were left submerged in wash buffer under gentle agitation for a total of
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15 minutes to remove any unreacted AcCoA. During this process, buffer was discarded
and replaced with fresh wash buffer every 5 minutes. The papers were then dried with
acetone and added to 4 ml of scintillation fluid, and the signal was measured using a
Packard Tri-Carb 1500 liquid scintillation analyzer. Background control reactions were
performed in the absence of enzyme. Reactions were also performed in the absence of
the substrate peptide to ensure that any possible signal due to autoacetylation was
negligible.

The background signal was accounted for when calculating catalytic

parameters for the wild type enzyme and mutants. All radioactive count values were
converted to molar units using a standard curve created with known concentrations of
radioactive AcCoA added to scintillation fluid. The program GraphPad Prism version
5.01 was used for all data fitting to the Michaelis-Menten equation.
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